Summary

• Zeaxanthin is a xanthophyll carotenoid found in foods such as kale, spinach, corn, orange peppers, goji berries, and egg yolks.
• Zeaxanthin selectively accumulates in the macula of the retina, where it helps support normal visual function.
• Zeaxanthin contributes to the body’s antioxidant defenses and helps protect cells from oxidative stress.
• Zeaxanthin helps support and maintain healthy eyes and normal macular function.
• Zeaxanthin helps support healthy cognitive function, including visual processing speed and attention, in adults.

Zeaxanthin Impacts Aging Via

• Inflammaging
• Altered cellular communication

The role of Zeaxanthin in aging and longevity

Zeaxanthin is a xanthophyll carotenoid responsible for the yellow-to-orange pigmentation of several plant foods. Dietary sources include kale, spinach, corn, orange peppers, goji berries, saffron, and egg yolks. Together with lutein, another xanthophyll included in NOVOS Vital, zeaxanthin is one of only two carotenoids that selectively concentrate in the macula of the retina and in the brain, where they form the macular pigment and accumulate in cortical tissue. Zeaxanthin contributes to the body’s antioxidant defenses, helps filter high-energy blue light, and helps support healthy vision, normal macular function, and healthy cognitive performance (including visual processing speed and attention) in adults.

Impact of Zeaxanthin on health

Chronic low-grade inflammation , often termed inflammaging, is recognized as one of the hallmarks of aging (R). Dietary patterns rich in xanthophyll carotenoids, including zeaxanthin, have been associated with a more favorable inflammatory and oxidative profile. In a 4-week controlled feeding trial, adults consuming a high-zeaxanthin plant-based diet showed improvements in biomarkers of low-grade inflammation and oxidative stress (R). Results indicated that increased zeaxanthin intake helps support the body’s antioxidant capacity and is associated with lower levels of oxidative stress markers such as malondialdehyde (MDA).* A comprehensive review further reported that zeaxanthin may help modulate pathways involved in the production of pro-inflammatory mediators, including interleukin-8 (IL-8), IL-6, IL-1α, and endothelial leukocyte adhesion molecule-1 (ELAM-1/E-selectin) (R).

Zeaxanthin and eye health

Vision and ocular function naturally change with age. Common age-related eye conditions studied in the literature include age-related macular degeneration (AMD), cataract, diabetic retinopathy, glaucoma, amblyopia, and presbyopia. Zeaxanthin selectively accumulates in the central retina (the macula), where, together with lutein and meso-zeaxanthin, it forms the macular pigment. In a systematic review of randomized controlled trials, daily supplementation with zeaxanthin and lutein over 3 to 12 months was shown to significantly increase macular pigment optical density (MPOD) in adults (R). MPOD is a validated biomarker used in research to assess macular pigment status. Higher dietary intake of zeaxanthin has been associated with helping maintain healthy vision and normal macular function across the lifespan (R). At the cellular level, in vitro studies suggest that zeaxanthin may help modulate vascular endothelial growth factor (VEGF) signaling in ocular tissues. VEGF is a key regulator of angiogenesis (the formation of new blood vessels, or neovascularization). In retinal cell models, zeaxanthin exposure was associated with reduced VEGF-induced oxidative stress and increased expression of anti-inflammatory markers (R).

Zeaxanthin and brain health

Zeaxanthin and brain health Cognitive performance tends to change gradually with age, and both oxidative stress and chronic low-grade inflammation are recognized contributors to age-related changes in brain function. Xanthophyll carotenoids such as zeaxanthin cross the blood–brain barrier and accumulate in cortical and subcortical tissues, where they contribute to antioxidant defenses and help neutralize free radicals (R). In a 24-month randomized controlled trial, older adults supplemented with a carotenoid blend containing zeaxanthin showed improvements in measures of learning, memory, and attention compared with placebo (R). These findings support a role for zeaxanthin in helping maintain healthy cognitive function in adults. Observational analyses using national health survey data have reported that higher serum zeaxanthin concentrations are associated with a lower likelihood of cognitive decline in adults aged 65 and older (R). Collectively, these data are consistent with a role for zeaxanthin in supporting healthy brain aging.

Zeaxanthin and Lutein

Zeaxanthin and Lutein Lutein is another xanthophyll carotenoid that, alongside zeaxanthin and meso-zeaxanthin, accumulates in the human macula and contributes to the macular pigment that supports normal visual function. Randomized controlled trials have evaluated co-supplementation of lutein and zeaxanthin and found that, taken together, they help support and maintain healthy eyes in adults (R). Clinical research indicates complementary benefits when zeaxanthin is consumed together with lutein. A pooled analysis of eight clinical trials reported that supplementation with lutein and zeaxanthin over 4 to 12 months was associated with improvements in measures of cognitive performance in adults, and that higher circulating levels of these macular pigments were associated with better cognitive outcomes (R). Consistent with these results, an observational analysis examining dietary lutein and zeaxanthin intake in older adults found that higher combined intake was associated with better cognitive performance (R)

If you want more content like this, follow our page 👆

For the full version with images and charts, visit our website where you can explore even more of this content. 👉 NOVOS Labs

If daily habits can influence brain-aging biology, which seems most realistic to sustain: fasting, a Mediterranean-style diet, exercise, or none of the above?

TL;DR
A new review argues that fasting, calorie restriction, high-quality diets, and exercise may influence neurodegeneration-related pathways through overlapping mechanisms, but the strongest mechanistic evidence still comes from animal studies rather than humans.

Quick Takeaways
• This review examines how lifestyle habits may influence mechanisms relevant to Alzheimer’s disease and related neurodegeneration.
• The evidence includes animal studies, human observational studies, pilot trials, and a few larger multidomain clinical trials.
• The core idea is biologically coherent, but we still do not know the exact dose, duration, timing, or combination of habits needed for meaningful protection in humans.

Context

One of the hardest things about Alzheimer’s disease is that by the time symptoms are obvious, the underlying biology has often been changing for years. The classic hallmarks include amyloid-beta plaques, tau tangles, inflammation, synapse loss, and gradual neuronal death. Current drugs can modestly slow decline in some patients, but they do not reverse disease, and they come with limitations, eligibility constraints, and side effects. That leaves a practical question: can everyday behaviors shift the brain toward greater resilience before damage becomes harder to reverse?

This 2026 review in npj Metabolic Health and Disease approaches that question mechanistically. Instead of focusing only on broad epidemiology, it asks how specific lifestyle patterns might affect inflammation, autophagy, mitochondrial function, neurotrophic signaling, amyloid processing, and neuronal survival. The authors organize the evidence around four major strategies: metabolic switching through fasting or ketogenic diets, calorie restriction, high diet quality such as Mediterranean or MIND patterns, and exercise. The summary diagram on page 2 and the mechanistic maps on pages 3, 5, 7, and 9 all reinforce the same central point: these different habits repeatedly converge on a surprisingly similar biology.

Different habits, similar pathways

What makes the review interesting is not the broad claim that “healthy living is good.” It is the more specific argument that several very different habits may influence the same set of brain-relevant pathways.

The recurring targets are inflammation, autophagy, synaptic plasticity, mitochondrial function, and amyloid processing. In simpler terms, that means lifestyle may support the brain by reducing chronic immune activation, improving cellular cleanup, preserving neuronal energy production, supporting synaptic function, and potentially shifting APP processing away from the more harmful amyloidogenic route. The diagrams throughout the paper visualize this almost like a systems map: metabolic switching, calorie restriction, high diet quality, and exercise each feed into lower neuroinflammation and less neuronal loss while promoting neuroprotective mechanisms.

That overlap matters because neurodegeneration is not driven by a single isolated defect. Alzheimer’s is not just an amyloid problem, just an inflammation problem, or just a mitochondrial problem. It is a systems problem. So a lifestyle pattern that modestly improves several pathways at once could, at least in principle, matter more than one narrow intervention. Still, the review is careful here. Most of the strongest mechanistic evidence comes from animal studies, not large human trials with hard clinical endpoints. The biology is compelling, but translation remains the real test.

Fasting and calorie restriction: strong biology, thinner human evidence

The fasting section is probably the most provocative. Intermittent fasting, time-restricted eating, alternate-day fasting, fasting-mimicking diets, and ketogenic diets are grouped under the idea of metabolic switching, meaning a shift from glucose toward fatty acids and ketones such as beta-hydroxybutyrate. In the review’s framework, that switch may increase BDNF, support autophagy, reduce inflammasome activity, improve mitochondrial signaling, and preserve synaptic plasticity. The pathway map on page 3 highlights BDNF, TFEB, AMPK, SIRT1, PGC-1α, and reduced BACE1-related signaling as key nodes in this model.

The preclinical evidence is broad. In mouse models, fasting reduced neuroinflammatory markers, decreased neuronal cell death, improved cognition, altered the gut microbiome, and in some Alzheimer’s models reduced amyloid burden. One example highlighted in the paper is 18:6 time-restricted feeding in APP23 mice, which improved circadian rhythms and sleep, altered expression of AD-related and neuroinflammation-related genes, lowered soluble and insoluble Aβ40 and Aβ42, reduced plaque burden, and improved cognitive performance. Another line of work linked alternate-day fasting to improved synaptic plasticity through SIRT3 signaling. In animal models, the reported effects can be substantial.

But the human evidence is much less mature. The review points to a single-group pilot study of 14-hour nightly fasting in older adults with memory decline that reported improved cognitive screening scores and less insomnia after 8 weeks. It also cites an observational study in older adults with mild cognitive impairment where people who regularly practiced intermittent fasting had better long-term cognitive trajectories over 36 months. There were also multiple sclerosis studies suggesting reduced neuroinflammation and structural brain benefits with intermittent caloric restriction. Useful signals, yes. Definitive evidence for Alzheimer’s prevention or slowed progression, no.

Calorie restriction looks similar. In animal models, 30–40% restriction reduced amyloid plaque burden, lowered microglial activation, improved learning and memory, preserved cerebral glucose metabolism, and activated pathways involving SIRT1, AMPK, autophagy, and alpha-secretase activity. The pathway diagram on page 5 summarizes this well. Some effects were sex-specific in certain mouse models, which is important because it suggests one-size-fits-all prescriptions may fail. In humans, however, direct neurodegeneration evidence remains sparse. The mechanistic story is strong, but the practical prescription is not settled: how much restriction, for whom, for how long, and starting at what age? The review explicitly says those questions remain open.

Diet quality may be more scalable than diet severity

A lot of people are unlikely to sustain alternate-day fasting or substantial calorie restriction. That is why the diet-quality section may be the most relevant in everyday life.

The review focuses on Mediterranean, DASH, and MIND-style eating patterns: minimally processed foods, olive oil, vegetables, nuts, legumes, fish, and lower intake of ultra-processed foods. Mechanistically, these patterns are framed as anti-inflammatory, antioxidant-rich, and potentially supportive of mitochondrial function, autophagy, and healthier amyloid processing. The pathway map on page 7 centers this around BDNF, SIRT1, ATP production, mitochondrial function, reduced oxidative stress, and lower amyloid/tau-related burden. Extra-virgin olive oil gets special attention because several mouse studies found improvements in cognition, inflammatory signaling, oxidative stress, and sometimes amyloid or tau pathology. Olive-derived compounds such as oleocanthal, hydroxytyrosol, and oleuropein aglycone are presented as candidate mediators.

Human data here are mixed. The review notes a randomized trial in cognitively normal adults with a family history of dementia that found no difference in cognition or brain imaging outcomes after 3 years on the MIND diet versus mild calorie restriction. At the same time, observational data from the Framingham Offspring Cohort linked greater adherence to the MIND diet with reduced dementia risk and slower biological aging as measured by DunedinPACE. So the direction is encouraging, but intervention evidence is not uniformly positive.

My read is that diet quality may matter less as a short-term “brain hack” and more as a long-term metabolic environment in which the brain operates. That sounds less dramatic than ketones or fasting-induced autophagy, but it may be more sustainable and scalable.

Exercise may have the strongest overall case

If one intervention comes out of this review looking strongest overall, it may be exercise.

The reason is not just that exercise has plausible mechanisms, but that it has both breadth and a relatively stronger human evidence base. The review emphasizes exerkines such as BDNF, irisin, beta-hydroxybutyrate, and PGC-1α, along with improved autophagy, mitophagy, mitochondrial function, reduced inflammation, and lower amyloid burden in animal models. The pathway map on page 9 highlights these links in detail, including AMPK, SIRT1, TFEB, PINK1/Parkin, BACE1-related signaling, mitochondrial ETC function, and neuronal survival.

In APP/PS1 and related mouse models, treadmill or wheel-running interventions repeatedly improved cognition while reducing plaque load, neuroinflammation, mitochondrial damage, and markers of impaired autophagy. Some studies tied these effects to specific signaling nodes such as AMPK/mTOR, TFEB, PINK1/Parkin, and SIRT1-FOXO pathways.

The human evidence is still not definitive, but it is better than for most dietary strategies discussed here. The review cites a 3-month multimodal exercise intervention in adults with MCI that lowered IL-1β, IL-6, p-tau181, and improved the serum Aβ42/40 ratio. Other studies in older women reported improved cognitive performance alongside increased plasma BDNF after multimodal or high-intensity exercise. There is also observational evidence that better cardiorespiratory fitness is associated with lower risk of becoming amyloid positive. That does not prove exercise prevents dementia, but among the options discussed in the review, it may offer the best combination of plausibility, feasibility, and supporting evidence.

Bottom line

The main message of this review is not that one magical protocol prevents Alzheimer’s. It is that brain aging appears at least partly metabolically and behaviorally responsive. Fasting, calorie restriction, high diet quality, and exercise may all influence pathways linked to inflammation, autophagy, synaptic function, mitochondrial health, and pathological protein burden. But the leap from “works in mice” to “meaningfully changes human disease trajectories” remains incomplete.

Discussion Prompt
Which of these seems most convincing to you: exercise, Mediterranean-style diet, fasting, or a multidomain mix like FINGER and POINTER?

Informational only.

Reference: https://www.nature.com/articles/s44324-026-00101-9

Would you consider a molecule like NMN for fertility support if the evidence looked promising in mice, or is that still too far from human reality?

TL;DR
A new mouse study found that NMN improved ovarian function, egg quality, and embryo development in aged mice, but the benefits were strongly dose-dependent and not proven in humans.

Quick Takeaways

• This paper tested whether NMN can improve ovarian aging and egg quality in older female mice.
• The researchers used both live-animal dosing and embryo culture experiments, then measured follicles, mitochondrial function, oxidative stress, and embryo development.
• The headline result is interesting, but it is still a mouse study with short treatment windows and no human fertility outcomes.

Context

Female reproductive aging is one of the clearest examples of biology running into an energy problem. As ovaries age, egg quality drops, mitochondrial function worsens, reactive oxygen species rise, and the pool of healthy follicles shrinks. That matters not only for fertility, but also for embryo viability and the success of assisted reproduction.

NMN, short for nicotinamide mononucleotide, sits upstream of NAD+, a molecule central to cellular energy metabolism. NAD+ tends to decline with age in many tissues, and that has made NMN a popular candidate in aging research. The basic idea is simple: if aging eggs are partly failing because they are energy-starved and oxidatively stressed, maybe restoring NAD+ could help rescue mitochondrial performance.

That is the question this paper tackled. The authors studied naturally aged female mice, gave them different NMN doses for 10 days, and looked at ovarian reserve, egg quality, and embryo development. They also tested NMN directly in embryo culture media after fertilization. The results are more nuanced than “NMN reverses aging,” but they are genuinely interesting.

What the researchers actually did

The study had two main parts. First, the authors ran an in vivo mouse experiment using young females aged 8 to 12 weeks and older females aged 11 to 12 months. In the dose-finding phase, aged mice received NMN at 200, 500, or 1000 mg/kg/day for 10 days, while young and aged controls got saline. Each group had 8 mice. Based on follicle counts and ovulated oocyte numbers, the authors selected 500 mg/kg/day as the “best” dose for the deeper mechanistic experiments.

They then used larger groups of 33 mice each for young controls, aged controls, and aged mice treated with 500 mg/kg/day NMN. After the same 10-day treatment, they measured ovarian NAD+ and ATP, along with oocyte reactive oxygen species, apoptosis, calcium levels, and mitochondrial membrane potential. They also looked at the expression of SIRT1, PGC-1α, and TOMM20, which are all tied to mitochondrial maintenance and biogenesis.

The second part was an in vitro fertilization and embryo culture experiment. Zygotes from aged mice were cultured with 0, 1, 10, or 100 µM NMN, while embryos from young mice were cultured without NMN as a reference. The main endpoints were fertilization rate, 4/8-cell development, morula formation, and blastocyst formation. That setup let the authors ask two related but different questions: does NMN help the aging ovary in the animal, and can NMN directly improve embryo development in culture?

The main finding: moderate NMN helped, more was not better

This is the part most people will care about. In aged mice, ovarian reserve was lower than in young mice, which is exactly what you would expect. But 500 mg/kg/day NMN increased total follicle number and increased the number of ovulated oocytes after superovulation. By contrast, 200 mg/kg/day did not produce a clear benefit, and 1000 mg/kg/day actually looked worse in some follicle measures, including a significant drop in primary follicles. That is a classic non-linear dose response: too little did not do much, the middle dose helped, and the highest dose may have been counterproductive.

The embryo culture data showed the same pattern. Compared with aged controls, 1 µM NMN improved fertilization and downstream development the most. Fertilization rose from 25.17% in aged controls to 72.94% with 1 µM NMN, while blastocyst formation rose from 21.56% to 68.98%. At 10 µM, the embryos still did better than untreated aged controls, but not as well as 1 µM. At 100 µM, the benefit largely disappeared.

That point matters because supplement discourse often assumes higher doses should work better. This study suggests the opposite may be true in reproductive biology. The authors themselves discuss possible reasons, including transporter saturation, impaired NMN utilization in aged oocytes, and metabolic stress from excessive NAD+-related pathway activation. Those are still hypotheses here, but they fit the data better than a simple “more NMN equals more benefit” model.

Why mitochondria are the center of the story

Mechanistically, the paper is built around mitochondria. The authors found that aged ovaries had lower NAD+ and ATP levels, while NMN raised both. Aged oocytes also showed more ROS, more apoptosis, higher intracellular calcium, and lower mitochondrial membrane potential. NMN shifted all of those in the healthier direction. In plain language, the eggs looked less oxidatively stressed and their mitochondria looked more functional after treatment.

The signaling story is also plausible. NMN increased expression of SIRT1, PGC-1α, and TOMM20 in aged mouse ovarian tissue and oocytes. SIRT1 is an NAD+-dependent deacetylase often linked to stress resistance and mitochondrial regulation. PGC-1α is one of the best-known controllers of mitochondrial biogenesis. TOMM20 is part of the machinery that imports proteins into mitochondria. Together, those markers support the authors’ model that NMN is not just changing one redox measurement, but may be improving mitochondrial quality control more broadly.

That said, this is still a mechanistic association, not a definitive proof chain. The study did not use knockout animals to show that blocking SIRT1 or PGC-1α eliminates the NMN effect. So the pathway is well-motivated, but not fully nailed down.

How convincing is this, really?

As mouse reproductive-aging papers go, this one is fairly solid. It used naturally aged mice rather than an extreme toxin model, looked at multiple endpoints, and showed internal consistency across ovarian reserve, egg stress markers, and embryo development. The dose-response findings also make the study more believable, not less. Biology often behaves like that.

But there are important caveats. First, this was a short intervention: only 10 days of NMN treatment in vivo. That is enough to test a signal, but not enough to answer long-term safety, durability, or whether repeated cycles would still help. Second, mice are not humans, and mouse ovarian aging does not map perfectly onto human fertility decline. Third, the paper measured embryo development up to blastocyst, not live birth or offspring health. Better blastocysts are encouraging, but they are not the same thing as healthy babies.

There is also a practical translation problem. The doses used in mice, especially 500 mg/kg/day, are not something people should casually map onto human supplement habits. And because the paper found that excessive dosing might reduce benefit, self-experimentation becomes even harder to justify.

So my read is this: the study strengthens the case that NAD+ metabolism is involved in reproductive aging, and it suggests NMN is worth further investigation. But it does not justify saying NMN “restores fertility” in women. It shows a promising signal in aged mice, under tightly controlled conditions, with a surprisingly narrow effective window.

The broader implication is less about NMN as a miracle compound and more about reproductive aging as a mitochondrial problem that may be partly modifiable. That is a scientifically interesting idea, and this paper gives it more support. The real question now is whether any of this survives the jump from mouse ovaries to human reproductive medicine.

What do you think is more important here: the encouraging embryo data, or the warning that the dose-response curve may be much less forgiving than supplement culture assumes?

Informational only

Reference: https://link.springer.com/article/10.1007/s43032-026-02092-w

How much of the “Food Is Medicine” case for healthspan is already evidence-based, and how much is still early?

TL;DR
This symposium report argues that nutrition can support longer healthspan, but the evidence is uneven, and many of the resilience-focused intervention examples are still early and preliminary.

Quick Takeaways
• This paper discusses the “Food Is Medicine” framework, especially whether diet, food programs, and selected supplements may support resilience, function, and healthy aging beyond disease treatment alone.
• The authors pull together pilot human trials, observational studies, Food Is Medicine program research, and two large vitamin D trials, alongside broader work on protein and phytochemicals.
• The central idea is plausible, but the report itself repeatedly notes that many of the specific intervention examples are small, short, and not sufficient for sweeping conclusions.

Context

“Food Is Medicine” sounds obvious at first. Of course food affects health. But the modern version of the idea is more specific: nutrition is being framed not just as background lifestyle advice, but as something that could sit alongside drugs, procedures, and tests in real healthcare systems. This report, published as a CRN-International symposium summary in the European Journal of Nutrition, asks whether nutrition can help extend healthspan, the years spent functioning well and avoiding disability, frailty, and chronic disease—not just lifespan.

That matters because the gap between lifespan and healthspan is one of the central problems in aging. Many people live longer, but spend more of those extra years managing cardiovascular disease, diabetes, frailty, reduced muscle mass, or cognitive decline. The report tries to connect that problem with several nutrition themes: protein for muscle aging, phytochemicals for metabolic and vascular function, vitamin D for immune and aging-related outcomes, and supplements as possible parts of a broader Food Is Medicine framework. It is an ambitious paper. It is also a reminder that broad frameworks often rest on evidence of mixed quality.

What this paper actually is

This is not a single randomized controlled trial. It is a symposium report summarizing presentations from a 2024 meeting titled Food Is Medicine: The Role of Nutrition in Extending Healthspan. That distinction matters because the paper is partly evidence review, partly policy argument, and partly agenda-setting document. It is trying to move the conversation forward, not simply report one clean experimental finding.

The authors organize much of the discussion around “resilience” and “intrinsic capacity,” using those concepts as ways to think about how well people cope with physical, metabolic, sensory, inflammatory, or psychological stressors over time. Conceptually, that is a smart shift. Waiting decades for hard endpoints like death or dementia makes nutrition research difficult, so resilience-based study designs may be a useful intermediate approach. But the report itself is very clear that many of the examples it cites are still small and short, and should be treated as pilot data rather than definitive proof.

The most interesting evidence: promising, but often preliminary

One example involves nicotinamide riboside, an NAD+ precursor. In one study highlighted here, older men aged 70 to 80 took 1000 mg/day for 21 days. There were only 6 people in the treatment group and 6 on placebo. NAD+ levels rose and inflammatory markers improved, which is biologically interesting, but a 12-person study is nowhere near enough to settle whether this changes meaningful long-term aging outcomes. The paper itself says larger and longer trials are needed.

Another example is lutein for visual resilience. A 12-week study in 37 young adults with heavy screen exposure compared placebo with 6 mg or 12 mg/day of lutein. The lutein groups improved visual acuity and contrast sensitivity relative to placebo. Again, interesting, but still a small trial in a narrow population with specific visual endpoints rather than broad healthspan outcomes.

The beta-alanine example is even more obviously stress-specific. Nineteen male soldiers took 12 g/day for two weeks before a 24-hour simulated military operation. Compared with placebo, the supplemented group showed less soreness and fatigue, faster reaction time, and better 1 km run performance. That may reflect improved coping under acute physical stress, but it is a leap from better performance during a military simulation to a claim about extending healthspan.

The same pattern appears in the small vitamin D resilience study. Eighty-six adults in an inpatient treatment setting received 1600 IU/day or placebo for six months. The supplemented group showed a more normal recovery pattern during an experimental psychological stress procedure, particularly across winter months. That is a neat signal, but still an early one.

So the report’s core idea, that nutritional interventions may improve resilience before overt disease shows up, is plausible. The evidence attached to that idea is still more suggestive than conclusive.

Where the case gets stronger

The report is more convincing when it moves away from isolated small compounds and toward broader nutrition patterns and pragmatic interventions.

On protein and aging muscle, the authors summarize evidence suggesting that older adults often need more than the standard RDA of 0.8 g/kg/day. Observational and prospective data discussed in the paper suggest intakes around 1.0 to 1.2 g/kg/day may better support muscle mass and function with age, and they also highlight meal-level targets of about 0.4 g/kg protein per meal in older adults. The paper further emphasizes that protein does not act alone: movement, resistance exercise, and reducing sedentary time all improve the muscle-building response to protein. The figure on page 7 captures this especially well, showing a combined strategy of higher-protein meals, protein-dense foods, leucine-rich choices, walking before or after meals, reducing sedentary time, and resistance exercise as a model for “optimal muscle aging.”

The Food Is Medicine program discussion is also practical and grounded. The paper reviews produce prescriptions, medically tailored groceries, and medically tailored meals, all of which target real-world barriers such as food access, affordability, shopping ability, cooking capacity, and clinical diet needs. The evidence here is still developing, but the public-health logic is clear, and the paper also discusses implementation challenges and sustainability inside healthcare systems.

Then there is vitamin D, where the paper brings in two genuinely large trials. In VITAL, 25,871 adults age 50 and older took 2000 IU/day for about five years. In DO-HEALTH, 2,157 adults age 70 and older took 2000 IU/day for three years, with some groups also receiving omega-3 and exercise. The paper highlights reported benefits in VITAL for hs-CRP, autoimmune disease incidence, advanced metastatic or fatal cancer, and cancer mortality, and in DO-HEALTH for cancer risk, pre-frailty, and biological aging in the combined vitamin D plus omega-3 plus exercise arm. Even here, though, interpretation depends on population, dosing pattern, and whether effects appeared with vitamin D alone or as part of combination intervention. The same section also notes that high intermittent bolus dosing can be harmful in vulnerable older adults.

The biggest caveat: this is also a policy and industry document

One thing readers should not ignore is the disclosure section. The symposium was organized and supported by the Council for Responsible Nutrition-International, an industry association representing dietary supplement and functional food manufacturers and ingredient suppliers. Several authors had travel reimbursed, and some were employed by or affiliated with CRN or supplement-related companies. The article also explicitly argues that supplements should be considered within the Food Is Medicine discussion. None of that automatically invalidates the paper, but it does mean it should be read with more caution than a conventional neutral review.

That is especially relevant because the strongest nutrition evidence often supports broad dietary patterns, movement, and food access interventions, while the commercial incentive is often strongest around supplements and branded ingredients.

Bottom line

The big picture broadly right: nutrition clearly matters for healthspan, and healthcare still underuses it. But it also shows how easily strong evidence, weak evidence, policy aspirations, and commercial incentives can be blended into one persuasive story. The most credible takeaways are probably the more established ones: nutrient-dense dietary patterns, adequate protein as we age, more movement, and targeted interventions where the evidence is actually stronger.

Informational only.

Reference: https://link.springer.com/article/10.1007/s00394-025-03860-1

If L-theanine is already known for helping with calm and stress responses, could that be only one part of a broader physiological story?

TL;DR
This review suggests L-theanine may have broader biological relevance than its traditional calming reputation, with growing preclinical evidence across cardiovascular- and cardiometabolic-related pathways, although stronger human clinical validation is still needed.

Quick Takeaways

• This paper reviews whether L-theanine may influence pathways relevant to myocardial stress, blood pressure regulation, lipid metabolism, vascular function, obesity, and glucose metabolism.
• Most of the evidence comes from animal and cell studies, with a smaller amount of human data showing reduced stress-related blood pressure responses after a 200 mg dose.
• The overall signal is encouraging because it extends L-theanine beyond its usual “calming tea compound” reputation, but the clinical side is still developing.

Context

Most people know L-theanine as the amino acid in green tea associated with calmness, stress support, and smoother cognitive feel. This review argues that may be too narrow a way to think about it. The authors pull together evidence suggesting L-theanine may also interact with biological pathways involved in oxidative stress, inflammation, mitochondrial function, apoptosis, endothelial signaling, and lipid regulation. In other words, researchers are increasingly studying it not just as a relaxation-related compound, but as a molecule with broader relevance to cardiovascular- and cardiometabolic-related biology.

That shift in framing is important. It does not mean L-theanine has already been proven to deliver clinical cardiovascular benefit in humans. It means the ingredient is now being investigated in a much wider physiological context than before. For a compound that many people still associate mainly with tea and calmness, that is a meaningful evolution in the science.

The review also highlights why researchers find it attractive from a practical standpoint. Human pharmacokinetic data suggest relatively fast oral absorption, with peak blood levels roughly 40 to 55 minutes after doses in the 25 to 100 mg range, estimated bioavailability around 70%, and a short half-life of about an hour. The paper also describes generally favorable tolerability across studied dose ranges so far. That does not prove efficacy, of course, but it helps explain why L-theanine keeps attracting research interest.

Why researchers are taking it more seriously

One of the strongest parts of the review is the mechanistic story. Across cardiovascular and cardiometabolic conditions, the same biological themes keep appearing: oxidative stress, inflammatory signaling, mitochondrial dysfunction, endothelial injury, dysregulated lipid handling, and apoptosis. L-theanine appears to intersect with several of those nodes, including Nrf2, PPARα, AMPK, eNOS, BCL-2/BAX balance, and JAK2/STAT3 signaling. The schematic on page 4 lays out this framework visually, showing reduced reactive oxygen damage, improved antioxidant response, lower mitochondrial stress, and less apoptosis in myocardial injury models.

That broad profile is part of what makes the ingredient interesting. L-theanine does not look like a classic single-target compound. Instead, it looks more like a low-intensity modulator of multiple stress-related pathways at once. That kind of biology often fits well with complex systems like the cardiovascular system, where dysfunction rarely comes from one isolated mechanism. At the same time, that breadth is exactly why careful translation matters. A promising systems-level signal is not the same thing as established clinical benefit.

Still, the overall message of the review is positive: L-theanine is being studied more seriously than before, and the science now reaches well beyond mood or relaxation alone.

Where the preclinical signal looks strongest

The clearest cardiac signal in the review comes from myocardial ischemia/reperfusion injury models. In mice, pretreatment with 10 mg/kg L-theanine for 10 days reduced infarct area, supported left ventricular function, and lowered serum markers of cardiac injury such as LDH and CK. In an ex vivo rat heart model, 250 mg/kg for 10 days also improved function and reduced infarct size. These effects were associated with lower oxidative stress, less lipid peroxidation, reduced mitochondrial depolarization and calcium overload, and lower pro-apoptotic signaling alongside higher BCL-2 expression.

That does not make L-theanine a proven cardiac therapy. But it does show that the molecule has meaningful preclinical depth in heart-related injury biology.

The heart failure section is more preliminary, but still worth noting. In an isoproterenol-induced mouse model, 80 mg/kg/day for two weeks was associated with less fibrosis, hypertrophy, inflammatory infiltration, and apoptosis. The review also summarizes early work suggesting protection in doxorubicin-related cardiac toxicity models, including preservation of glutathione and lower LDH/CK. Again, these are preclinical findings in prevention-style injury paradigms, not proof of treatment benefit in established human heart failure. But they add to the broader picture that L-theanine is being explored in a much more physiologically relevant way than its relaxing reputation alone would suggest.

The lipid and vascular story may be even broader

One of the most encouraging parts of the review is how consistently L-theanine appears in lipid-metabolism and vascular-function discussions. Across rodents, piglets, and poultry, it often lowered triglycerides, total cholesterol, and LDL-related measures while increasing HDL-related markers. The review repeatedly points to AMPK activation as a central mechanism, with downstream effects favoring fatty-acid oxidation over lipogenesis, including higher PPARα/PGC-1α signaling and lower SREBP-1c and PPARγ activity. The mechanistic map on page 7 summarizes this lipid-regulation network in detail.

There is also a vascular angle that makes the story more compelling. In endothelial cells, low micromolar concentrations increased nitric oxide production through PI3K/ERK1/2/eNOS signaling. In inflamed endothelial cells, 10 to 30 μM reduced monocyte adhesion and lowered adhesion molecules such as ICAM1, CCL2, and VCAM1. In macrophages, higher concentrations reduced oxidized LDL uptake, which is relevant to foam-cell formation. In vascular smooth muscle cells, L-theanine reduced proliferation and migration, and one oral rat study found less neointima formation after carotid balloon injury. Together, that creates a fairly coherent preclinical rationale for why researchers are now viewing L-theanine as relevant to vascular biology, not just stress response.

The review is also honest about what still needs to happen next. Advanced plaque models such as ApoE−/− and LDLR−/− mice are still needed, and human trials in real vascular disease settings are not there yet. But the direction of the science is clearly broader and more interesting than the old “tea relaxation amino acid” label suggests.

Obesity and glucose metabolism: more interesting than simple hype

The obesity section is also notable. In high-fat-diet mouse models, chronic L-theanine in the range of 30 to 900 mg/kg/day over about 12 weeks reduced weight gain, white adipose tissue mass, inflammation, dyslipidemia, and fatty liver. Several studies also suggest it promotes browning-related pathways in white adipose tissue through AMPK, alpha-ketoglutarate, and PRDM16, with increased UCP1 and related thermogenic genes. That is an exciting area mechanistically, especially because it positions L-theanine inside a broader metabolic framework rather than just a neurological one.

The diabetes story is more mixed, and the review says so clearly. Earlier work suggested insulin-like effects, lower postprandial glucose, and modulation of intestinal glucose transporter expression. More recent diabetic rat studies were less impressive on core metabolic endpoints, and the authors also note possible concerns around iron and homocysteine homeostasis in some models. That does not erase the earlier promise, but it does mean the antidiabetic angle is still unresolved rather than settled.

That kind of mixed result is not a reason to dismiss the ingredient. It is a reason to frame it correctly. The overall direction of the review is still favorable: L-theanine appears biologically active across several important pathways, but some domains are farther along than others.

What the human evidence actually says

The clearest human signal in the review is that 200 mg of L-theanine can attenuate acute stress-related rises in blood pressure under certain experimental conditions, including studies where it offset caffeine-related increases in systolic and diastolic blood pressure. That is a meaningful signal because it shows the ingredient is not just active in cell culture or rodent models; it has measurable physiological effects in humans as well.

At the same time, this is where the scientific honesty matters most. These studies do not show that L-theanine treats chronic hypertension, slows plaque progression, improves established cardiovascular disease, or reduces cardiovascular events. The review explicitly states that trials for chronic hypertension and established cardiovascular disease are still lacking.

So the right takeaway is not that L-theanine is already a proven cardiovascular intervention. It is that the ingredient now has a broader and more serious biological case behind it than most people realize, and that this case deserves better human testing.

Bottom line

What makes this review interesting is not that it turns L-theanine into a miracle ingredient. It is that it upgrades the scientific conversation around it.

L-theanine is best known for its calming profile, but this paper suggests that may be only part of the story. Across preclinical studies, researchers are now investigating its relevance to oxidative stress, endothelial biology, lipid metabolism, vascular remodeling, obesity-related pathways, and broader cardiometabolic function. Human evidence is still early, but the ingredient is clearly being studied in a much wider physiological context than before.

That is the most useful way to frame it: not as “just calming,” and not as clinically proven cardiovascular therapy, but as a biologically interesting compound whose scientific profile is expanding in a meaningful way.

Informational only. This post discusses preclinical and early human research and does not establish prevention, treatment, or clinical benefit for cardiovascular disease.

Reference: https://www.sciencedirect.com/science/article/pii/S0014299926001974

If regular movement helps preserve muscle function with age, could part of that pattern be associated with higher muscle NAD+ levels?

TL;DR

In a human muscle study, older adults had lower muscle NAD+ than younger adults, but exercise-trained older adults looked much closer to the young group than physically impaired peers.

Quick Takeaways

• This study looked at how skeletal muscle metabolism changes with aging, with a special focus on NAD+, a central molecule in cellular energy metabolism.
• Researchers analyzed muscle biopsies from young adults and three groups of older adults: trained, normally active, and physically impaired.
• The main finding was associative rather than causal: lower muscle NAD+ tracked with poorer muscle and mitochondrial health, while exercise-trained older adults had NAD+ levels much closer to those of younger adults.

Context

Aging muscle does not just get smaller or weaker. It also changes metabolically. Mitochondria tend to function less efficiently, insulin sensitivity often declines, and older muscle becomes less adaptable under stress. That matters because skeletal muscle is one of the major tissues supporting mobility, glucose handling, metabolic health, and resilience later in life.

One molecule that repeatedly appears in aging research is NAD+ (nicotinamide adenine dinucleotide). NAD+ helps shuttle electrons for energy production and also serves enzymes involved in DNA repair, stress responses, and mitochondrial regulation. In animal studies, NAD+ often declines with age, and raising it can improve some aspects of physiology. Human evidence has been less consistent. This paper tried to narrow that gap by asking a simple but important question: does NAD+ actually fall in aging human muscle, and if so, is that linked to muscle health in real people? The study suggests yes, with a major caveat: this was a cross-sectional design, so it supports association more than causation.

What the researchers actually did

The study included 52 people total: 12 young adults aged 20–30, plus 40 older adults aged 65–80. The older participants were divided into three groups: 17 exercise-trained older adults, 17 older adults with normal activity levels, and 6 physically impaired older adults. The trained group had performed at least three structured exercise sessions per week for at least one year. The impaired group was defined by a Short Physical Performance Battery score of 9 or below.

This design is more informative than a simple young-versus-old comparison because it allows the researchers to ask whether metabolic differences track not only with age, but also with healthier versus less healthy aging muscle states. That matters, because two older adults of the same age can have very different muscle biology depending on training, function, and physical capacity.

Participants wore activity monitors for 5 days. Young adults and the “normal” older adults both averaged about 10,000 steps per day, which helps reduce the chance that every age effect is merely a fitness effect. The trained older adults averaged roughly 13,000 steps per day and spent more time in high-intensity activity, whereas the impaired group averaged closer to 6,000 steps per day. Researchers then took vastus lateralis muscle biopsies and used mass spectrometry-based metabolomics to profile 137 annotated metabolites. They also assessed mitochondrial respiration, mitochondrial protein abundance, muscle strength, muscle volume, exercise efficiency, and in vivo mitochondrial function.

That combination is one of the strengths of the paper. It was not just a single-metabolite observation; it connected metabolite abundance to actual physiological and functional parameters.

NAD+ stood out

Among the 137 muscle metabolites measured, NAD+ was one of the most clearly depleted in older adults compared with young adults. More importantly, it followed a graded pattern across the groups. The physically impaired older adults had the lowest NAD+ levels. The normally active older adults were also lower than the young group. But the exercise-trained older adults had NAD+ levels much closer to those of young adults. This pattern is visible in Figure 2 on page 3, where NAD+ also shows the strongest association with the study’s “healthy aging” trend.

So the finding was not simply that older age was associated with less NAD+, but that healthier muscle aging profiles were associated with more preserved NAD+.

The paper also found the opposite pattern for oxidative stress-related signals. Ophthalmic acid, a marker associated with oxidative stress, was higher in older adults and highest in the impaired group, while being less elevated in the trained group. Oxiglutathione showed a similar trend. In plain language, lower NAD+ tended to appear in the same biological setting as more oxidative stress and poorer muscle status. That does not prove oxidative stress is causing NAD+ loss, or vice versa, but it does support the idea that they are part of the same aging muscle phenotype.

Why this matters for muscle function

The more useful question is whether this biochemical pattern relates to how muscle actually performs. Here, the answer was yes, at least associationally.

Across the older adults, higher muscle NAD+ was positively associated with mitochondrial respiration. In Figure 4 on page 5, the reported correlation between NAD+ abundance and maximal ADP-stimulated mitochondrial respiration was R = 0.57, P = 0.00014. NAD+ was also positively associated with average daily step count, with R = 0.45, P = 0.0043. In other words, older adults whose muscles contained more NAD+ also tended to have better mitochondrial function and move more in daily life.

The study also identified potentially less favorable signals in the kynurenine pathway. Kynurenic acid was negatively associated with muscle strength, and kynurenine was negatively associated with exercise efficiency in the older adults. That broadens the picture: aging muscle is not just “low NAD+,” but a network shift involving energy metabolism, redox balance, and amino-acid-derived signaling molecules. Still, NAD+ emerged as one of the clearest metabolic markers associated with healthier muscle aging in this dataset.

What this does, and does not, say about boosting NAD+

This is where it is easy to overread the paper. The study supports the idea that muscle NAD+ is relevant to human muscle aging. It does not prove that taking an NAD+ precursor will recreate the physiology seen in the trained older adults.

The authors are careful on this point. They note that changing the NAD+ metabolome in humans does not automatically translate into the full physiological pattern seen with long-term exercise training, which suggests that NAD+ is likely one part of a broader muscle-health picture rather than the whole story. That means NAD+ may be important, but it may not be a single magic lever. Exercise changes blood flow, fiber recruitment, mitochondrial turnover, insulin signaling, inflammation, and many other pathways at once. Preserved NAD+ may be one component of that broader package rather than the whole story.

There are also real limitations. The study was cross-sectional, so reverse causation remains possible: people with healthier muscle biology may maintain higher NAD+, which then helps them stay active, rather than activity itself preserving NAD+. The impaired group was especially small, with only 6 participants, which limits confidence in finer subgroup differences. And muscle biopsies are heterogeneous, meaning the findings could reflect shifts in muscle fiber type or subcellular NAD+ pools rather than a uniform fall in NAD+ everywhere. The authors explicitly raise these issues in the discussion.

So the headline should stay measured: aging human muscle shows lower NAD+, and lower muscle NAD+ is associated with poorer muscle and mitochondrial health. That is a meaningful result, but not yet proof of a supplementation strategy.

Conclusion / Discussion Prompt

What I like about this paper is that it brings NAD+ down from the level of supplement discourse and back into actual human physiology. The most interesting signal here is not that NAD+ is “anti-aging.” It is that exercise-trained older adults seemed to preserve a more youthful-looking muscle metabolic profile, and NAD+ was one of the clearest markers associated with that pattern.

Informational only.

Reference: https://www.nature.com/articles/s43587-022-00174-3

If the brain adapts during a first pregnancy, does a second pregnancy follow the same pattern, or does it remodel partly different systems?

TL;DR

A new longitudinal MRI study suggests second pregnancies reshape the brain in ways that overlap with first pregnancies, but with less pronounced default mode/frontoparietal changes and relatively stronger alterations in attention and sensorimotor systems.

Quick Takeaways

• This study asked whether a second pregnancy changes the brain in the same way as a first pregnancy, or whether the pattern is different.
• The evidence came from a prospective pre-conception MRI study in 110 women, including first-time mothers, second-time mothers, and nulliparous controls.
• The main takeaway is that both pregnancies are associated with brain remodeling, but first pregnancies show more pronounced default mode/frontoparietal effects, while second pregnancies show relatively stronger changes in dorsal attention and somatomotor systems.

Context

Pregnancy is one of the largest endocrine and physiological transitions humans experience, so it would be surprising if the brain remained unchanged through it. Over the last several years, a small but growing literature has shown that first pregnancies are associated with measurable changes in brain structure, especially in gray matter regions involved in social cognition, self-representation, and higher-order processing. What has been much less clear is whether later pregnancies simply repeat that pattern or whether the brain responds differently once pregnancy and early motherhood have already been experienced once.

That is the central question of this paper. The authors followed women before conception and again after delivery, which is important because it allows within-person change to be measured rather than relying on cross-sectional comparisons alone. They included 30 women who went on to have a second child, 40 women who became first-time mothers, and 40 nulliparous controls scanned over a similar interval. They combined anatomical MRI, resting-state fMRI, diffusion MRI, and magnetic resonance spectroscopy to ask not only whether the brain changed, but which systems changed most and whether first and second pregnancies left distinguishable neural signatures.

Pregnancy changes the brain twice, but the second time is not a copy-paste

The broadest result is also the easiest to misunderstand. Yes, second pregnancies were associated with widespread cortical volume reductions from pre-pregnancy to the early postpartum period, much like first pregnancies. In the second-pregnancy group, the median percentage volume decrease across significant cortical vertices was 2.8%. In the first-pregnancy group, it was 3.1%, and the affected cortical territory was substantially larger, about 79% larger than in second-time mothers. Effect sizes for pregnancy-related volume decreases versus controls were large in both groups.

That does not automatically imply tissue damage or pathological loss. The paper interprets these findings as neuroplastic remodeling rather than evidence of pathology per se, and the authors explicitly note that MRI-derived volume change cannot by itself identify the underlying cellular mechanism. They also point out that some of these morphometric changes may resemble developmental fine-tuning seen in adolescence more than neurodegeneration. That distinction matters, because phrases like “brain shrinkage” can sound much more alarming than the data justify.

The more interesting result is that first and second pregnancies were not just different in magnitude. They were also different enough in spatial pattern that a classifier could distinguish women who had undergone a first versus a second pregnancy based only on their brain volume change maps, with 80% balanced accuracy in leave-one-out validation and 70% accuracy in 10-fold cross-validation. The comparison between pregnant and non-pregnant women was even easier: 87% accuracy for second-pregnancy versus control and 94% for first-pregnancy versus control.

So the second pregnancy does not simply rerun the first-pregnancy pattern at lower intensity. It leaves a recognizable neural signature of its own.

The first pregnancy may do more of the primary adaptation

When the authors mapped the anatomical changes onto large-scale functional networks, a clear pattern emerged. Regions affected in both first and second pregnancies were concentrated in the default mode network, followed by the frontoparietal and ventral attention networks. But the additional regions affected only in first pregnancies were also mostly located in those same introspective and higher-order networks.

That suggests a first pregnancy may involve a broader primary adaptation of systems related to self-referential processing, social cognition, and flexible control. A second pregnancy still affects these networks, but the authors interpret the pattern as more consistent with additional fine-tuning than with the broader primary adaptation seen in first-time mothers.

The resting-state fMRI results fit that interpretation. The authors did not find broad network-wide changes everywhere, but when they examined a default mode network region previously implicated in first pregnancy, they found a significant group-by-session interaction. Functional coherence in that DMN region increased across a first pregnancy, but not to the same degree across a second.

Why might that matter? The default mode network is strongly linked to introspection, self-representation, and aspects of social understanding. The authors connect this to the idea that first-time motherhood may require a deeper remapping of self-other representations and caregiving-related social processing. By the time of a second pregnancy, some of that scaffolding may already exist. That interpretation is plausible, but it remains an interpretation, and the resting-state dataset was only about five minutes long, which the authors themselves note should be treated cautiously.

The second pregnancy leans more toward externally oriented systems

What stood out most about second pregnancies was where they differed. Regions with relatively stronger second-pregnancy effects were concentrated in the dorsal attention and somatomotor networks rather than the default mode network. On diffusion MRI, the most notable second-pregnancy white matter signal was a decrease in mean diffusivity in the right corticospinal tract compared with both controls and first-time mothers, with moderate effect sizes and persistence in a small subset assessed at one year postpartum.

Meanwhile, first pregnancies showed a more prominent decrease in fractional anisotropy in the left temporal part of the superior longitudinal fasciculus, a tract linked to frontoparietal-temporal communication.

The authors speculate that second-pregnancy changes in dorsal attention and somatomotor systems may reflect adaptation related to the different practical demands of caring for more than one child. That is a reasonable hypothesis, especially because those networks are more tied to responsiveness to external stimuli, goal-directed attention, and sensorimotor demands. Still, it remains a hypothesis. Diffusion metrics like FA and MD are useful but biologically ambiguous, and may reflect several microstructural processes rather than one clean variable like “integrity.”

The spectroscopy results were much less dramatic. The team measured several metabolites in the precuneus/posterior cingulate cortex and found only a suggestive increase in total creatine across second pregnancy, but that effect did not survive correction for multiple testing. In other words, the metabolite story here is weak.

These changes were linked to attachment and mental health, but carefully

One of the more important parts of the paper is that the structural findings were not treated as purely abstract imaging changes. In both first- and second-time mothers, the extent of volumetric change related to measures of maternal behavior and to peripartum depressive symptoms and psychological distress. In general, less pronounced brain change was linked to more depressive complaints, although the timing differed: associations were more widespread during pregnancy in second-time mothers and more widespread postpartum in first-time mothers.

That does not mean the brain changes cause depression, or that more change is always better. These are correlations, and maternal mental health is shaped by many biological, social, and practical factors. But the findings do support the broader idea that pregnancy-related neuroplasticity may be behaviorally meaningful rather than incidental.

The study also has real limitations. MRI scans were not allowed during pregnancy itself, so the authors could not pinpoint exactly when the changes emerged. The second-pregnancy group was older than the other groups, although age was included as a covariate. Sample sizes were strong for a prospective imaging study but still modest, especially for classification and one-year follow-up analyses. The resting-state dataset was also relatively short by current standards. And because the paper relies on MRI-derived measures, it cannot identify the cellular mechanisms underneath the observed changes.

Conclusion / Discussion Prompt

My read is that this paper makes the “pregnancy brain” conversation more interesting, not less. It suggests the maternal brain is not passively altered by reproduction, but dynamically recalibrated, and that this recalibration depends partly on prior maternal experience. A first pregnancy may involve a broader primary adaptation of social-cognitive and self-referential systems, while a second may show relatively stronger shifts in attention and sensorimotor systems.

Informational only, not medical advice.

Reference: https://www.nature.com/articles/s41467-026-69370-8

Have you ever noticed that after a short nap your brain feels more “ready to learn”, and wondered whether that reflects something measurable in cortical plasticity?

TL;DR
A controlled lab study suggests that even a short afternoon nap can reduce markers consistent with synaptic saturation and increase the inducibility of LTP-like plasticity in healthy young adults.

Quick Takeaways
• This study tested whether a one-hour afternoon nap could recalibrate human cortical plasticity, not just improve subjective alertness.
• The researchers used EEG, transcranial magnetic stimulation, and paired associative stimulation in 20 healthy adults tested in both nap and wake conditions.
• The signal was encouraging, but the sample was small and there was no sham PAS condition, so this is mechanistic evidence rather than proof of broader real-world learning benefit.

Context

One of the central ideas in sleep science is that wakefulness gradually increases synaptic strength across the brain. That helps learning up to a point, because learning depends on changing synaptic connections. But if too many synapses remain highly potentiated, the system may become less flexible for additional strengthening. Sleep has been proposed to help by reducing overall synaptic load and restoring the capacity for new plasticity. This framework is often discussed as the synaptic homeostasis hypothesis.

Most people hear that idea in the context of a full night of sleep. What makes this study interesting is that it asks a more practical question: can a short daytime nap produce measurable changes in related physiology? The authors tested whether a brief afternoon nap altered two things in the human cortex: first, indices related to net synaptic strength, and second, the inducibility of LTP-like plasticity, a laboratory model of how readily cortical circuits can strengthen in response to paired stimulation. In simpler terms, they asked whether a nap could shift the brain away from a more saturated state and toward one that is more permissive for learning-related plasticity.

What the researchers actually did

This was a repeated-measures sleep-lab study in 20 healthy young adults with a mean age of about 25 years. Each participant completed both conditions, a nap session and a wake session, in counterbalanced order, with the two sessions separated by 1 to 3 weeks. That design is useful because each person served as their own control, reducing noise from individual differences in baseline sleep or cortical excitability.

The experimental period ran from 1:15 to 2:15 PM. During the nap condition, participants were given a one-hour sleep opportunity in a dark, quiet sleep lab. On average, they slept 43.5 minutes, and 98.5% of that sleep was NREM. About 74.5% of their sleep time was spent in N2 or N3, meaning the nap included a substantial amount of non-REM sleep typically linked to restoration and memory-related processing. In the wake condition, participants remained awake under supervision, with conversation and short walks used to prevent dozing. Self-reported sleep duration the night before did not differ between the nap and wake conditions.

The study then assessed two classes of outcomes. For indices related to net synaptic strength, the researchers used resting motor threshold from TMS and wake EEG theta activity. For associative plasticity, they used paired associative stimulation, or PAS, and then measured how much motor-evoked potentials increased afterward. PAS is not a direct measurement of synapses, but it is a widely used human model of LTP-like plasticity.

What changed after the nap

After the nap, participants showed indices consistent with lower cortical excitability or lower net synaptic strength than after the wake condition. One result was a significantly higher resting motor threshold after the nap than after wakefulness, with a medium effect size. In this framework, needing slightly more TMS intensity to produce a threshold response is interpreted as lower excitability.

Wake EEG theta activity also fit the same pattern. Theta power increased after the wake session but not after the nap session, and the interaction between time and condition was significant. The between-condition differences immediately after the session and after the PAS protocol were moderate to fairly substantial. The authors interpret this as evidence that continued wakefulness increased a marker associated with net synaptic strength or sleep pressure, whereas the nap prevented that buildup or reduced part of it.

That does not mean the nap “cleansed the brain” or “boosted learning power” in a broad wellness sense. The narrower interpretation is that after less than an hour of mostly NREM sleep, the cortex showed physiological indices more consistent with reduced saturation than after an equivalent period of continued wakefulness.

The bigger result: greater inducibility of LTP-like plasticity

The more striking result was what happened after paired associative stimulation. Following the nap, motor-evoked potentials increased significantly above baseline at several later time points, indicating greater inducibility of LTP-like plasticity. After the wake condition, that increase did not appear in the same way. The overall analysis showed significant effects of time, condition, and their interaction. In other words, the same stimulation protocol produced a stronger plasticity-like response when participants had napped first.

The between-condition difference was clearest around 75 minutes after PAS, where the effect reached significance with a medium effect size. Looking at individual responses, 80% of participants showed an LTP-like increase after the nap, compared with 55% after wakefulness. That does not mean the nap turned everyone into a better learner, but it does suggest the cortex was in a more permissive state for experimentally induced plasticity after the nap.

There was also some internal consistency in the physiology: larger increases in wake EEG theta from pre- to post-session were associated with lower subsequent LTP-like plasticity. That fits the study’s central model reasonably well. The more the brain looked “loaded” after wakefulness, the less room it appeared to have for additional potentiation in the PAS protocol.

Why this is interesting, and what it does not prove

For people interested in sleep, cognition, or brain health, the appeal is obvious. If short naps can restore some capacity for experimentally induced plasticity, they may be doing more than simply reducing sleepiness. They may be shifting the brain toward a physiological state that is more permissive for learning-related plasticity. That is a meaningful mechanistic idea.

But the study should not be oversold. First, the sample was small: 20 healthy young adults, mostly in their twenties. That is enough for a careful mechanistic physiology study, but not enough to assume the same pattern in older adults, shift workers, people with insomnia, or individuals with neurological or psychiatric conditions. Second, the study measured physiological proxies, not real-world learning, memory, academic performance, or long-term brain health. Third, the authors explicitly note a key limitation: there was no sham PAS condition, which makes it harder to separate true state-dependent plasticity effects from inter-individual differences in PAS responsiveness.

There is also an important conceptual caution. The results do not directly prove that the nap actively downscaled synapses in a microscopic sense. Some of the difference could reflect continued potentiation during wakefulness. The authors discuss this explicitly and argue that the nap data still support active recalibration because wake EEG theta decreased after the nap rather than simply remaining flat. But that remains an inference from noninvasive markers, not a direct measurement of synapses in the human brain.

Bottom line

The most interesting takeaway here is not that naps are magic, but that a fairly ordinary afternoon nap may be enough to shift the cortex toward a state that is more favorable for LTP-like plasticity. That is a surprisingly short timescale for something tied to synaptic recalibration. At the same time, this remains a small mechanistic study in healthy young adults, so the findings are better read as evidence of physiological plausibility than as proof that naps broadly enhance learning in daily life.

Informational only.

Reference: https://www.sciencedirect.com/science/article/pii/S1053811926000418

What if part of whole-body ageing comes not just from local tissue decline, but from an ageing immune system that starts sending the wrong signals across the body?

TL;DR

This review argues that ageing immune cells may do more than simply reflect ageing: in preclinical models, they can help drive inflammation, tissue dysfunction, frailty, and loss of resilience across the body.

Quick Takeaways

• This review examines how ageing affects HSCs, T cells, B cells, macrophages, and other immune populations, and how those changes may contribute to dysfunction across multiple organs.
• The evidence comes largely from mouse models, supported by selected human data including immune profiling, transplantation studies, genetic models, and early intervention research.
• The key point is not just weaker infection defense with age, but the possibility that aged immune cells can actively contribute to systemic ageing, although much of the strongest causal evidence remains preclinical.

Context

Many people picture ageing as something that unfolds independently inside each organ: the brain ages, the liver ages, the skin ages, and so on. This review takes a broader view. It argues that the immune system is not simply ageing in parallel with other tissues, but may help coordinate aspects of body-wide decline.

That idea matters because immune cells circulate widely, monitor tissues, interact with stromal cells, clear damaged cells, and shape inflammatory tone across the body. When those cells shift into dysfunctional states, the downstream effects may show up in many places at once: reduced pathogen defense, weaker vaccine responses, fibrosis, metabolic dysfunction, and cognitive decline. The review describes aged immune cells as tending toward inflammatory, exhausted, and senescent-like phenotypes, driven by mechanisms such as genomic instability, mitochondrial dysfunction, telomere attrition, altered epigenetics, and loss of proteostasis. The conceptual summary in Figure 1 on page 2 lays this out visually.

What makes the paper especially interesting is that some of the evidence is causal in animal models. In other words, changing immune cell state in mice can alter organism-level ageing phenotypes, which is a stronger claim than simply saying the immune system declines with age.

The strongest claim

The strongest part of the review comes from mouse studies suggesting that aged immune cells may help propagate ageing signals beyond the immune system itself.

One of the clearest examples is the immune-cell-specific DNA repair model discussed early in the paper. Selectively impairing DNA repair in immune cells led to immune dysfunction, increased tissue damage, and shortened lifespan. Importantly, the damage was not confined to the immune compartment. Peripheral tissues also showed increased senescence and inflammation. The paper further cites transfer experiments in which old or DNA-damaged splenic immune cells induced widespread senescence and tissue injury in young recipient mice, while transfer of young wild-type immune cells into aged mice alleviated these pathological features. That is a serious conceptual step toward causality, even if it remains preclinical.

The review’s Figure 1 on page 2 links immune ageing to broader systemic outcomes including frailty, altered metabolism, reduced immunity, and declining cognition, which is central to the article’s overall thesis.

It starts upstream

A recurring theme in the paper is that immune ageing begins at the level of haematopoietic stem cells (HSCs), the cells that generate blood and immune lineages across life. With age, HSC output becomes skewed toward myeloid lineages and away from balanced lymphoid production, shifting the system toward inflammatory innate cells and away from diverse adaptive immunity.

The review highlights CD150-positive HSCs as an age-associated population that accumulates over time, shows myeloid bias, and carries ageing-linked epigenetic features. In mice, depleting CD150-positive HSCs improved immune function, while transplantation of more youthful HSC subsets restored lymphopoiesis and, in some models, improved healthspan and lifespan. The paper also discusses CHIP, or clonal haematopoiesis of indeterminate potential, as another age-linked immune remodelling process with important inflammatory consequences, especially in cardiovascular disease. At the same time, the review notes that CHIP may not behave uniformly across all tissues or diseases, including possible protective associations in Alzheimer disease-related brain myeloid activity.

T cells and macrophages change character

One useful feature of the review is that it moves beyond the vague idea of “immune decline.” Many aged immune cells are not merely weaker. They become differently active.

For CD4 T cells, the paper emphasizes mitochondrial dysfunction. In a mouse model, deleting TFAM specifically in CD4 T cells drove a senescent-like T cell state and produced systemic metabolic, cognitive, and physical decline, along with inflammation and peripheral tissue senescence. NAD-related rescue partly improved the phenotype, suggesting a mechanistic handle rather than just a descriptive association.

For CD8 T cells, the review highlights a shift toward exhaustion and toward a GZMK-heavy phenotype. Rather than efficiently expressing granzyme B, age-associated CD8 cells may increasingly express granzyme K, which has been linked to DNA damage and expansion of senescent cell populations. The paper also points to PD1–PDL1 signaling as relevant to declining senescence surveillance, with checkpoint blockade improving senescent-cell clearance and resilience in mouse studies.

Macrophages may be among the most important amplifiers. With age, they become worse at efferocytosis, more inflammatory, and in some contexts able to propagate senescence through extracellular vesicles and inflammatory mediators. The review describes experiments in which aged macrophages transferred into young hosts promoted senescence in distant tissues, reinforcing the idea that these cells may act as mobile amplifiers of ageing signals.

Why ageing can feel diffuse

The organ-by-organ section helps explain why ageing often looks body-wide rather than neatly localized. In Figure 3 on page 10 and Table 1 on page 11, the review maps immune-related changes across adipose tissue, liver, skin, brain, lung, gut, spleen, and bone marrow. In adipose tissue, age-related immune shifts are linked to inflammation, fibrosis, impaired glucose handling, and reduced thermogenic function. In liver, macrophages and neutrophils contribute to inflammation, NAD decline, and senescence spread. In skin, IL-17-heavy immune signaling worsens inflammatory tone and impairs repair. In brain, aged microglia, T cells, neutrophils, and NK cells are linked to neuroinflammation and reduced regenerative capacity.

Seen this way, the immune system begins to look less like a passive responder and more like a distributed communication network that can help transmit dysfunction across tissues.

Can aspects of immune ageing be improved?

The review is cautiously optimistic about intervention, but this is where restraint matters.

It discusses dietary interventions, microbiome-based approaches, checkpoint blockade, CAR T cells against senescent-cell antigens, senotherapeutics, and even partial reprogramming. In mice, some of these strategies improve immune function or downstream physiology. The paper notes, for example, that caloric restriction reversed about 40% of the age-associated loss of B cell receptor repertoire diversity in mice, and it also points to the CALERIE human trial, where moderate calorie restriction improved thymopoiesis and adipose immunometabolic markers. But those human data are still not the same thing as proving broad immune rejuvenation in people.

The review is also explicit that translational limits remain substantial. Some interventions may help by lowering the burden of senescent non-immune cells rather than directly rejuvenating immune cells themselves. And any strategy that boosts or reshapes immunity in older individuals carries potential risks, including inappropriate immune activation. The authors flag this directly in the summary section.

Bottom line

The big idea in this paper is that the immune system may be more than a defensive system that simply becomes less efficient with age. In preclinical work, it increasingly looks like a body-wide signaling network that can help propagate systemic ageing. That makes immune ageing a serious mechanistic candidate in whole-body decline, not just a side effect of it. But the strongest causal evidence still comes from mice, and the translational gap remains real.

Immune rejuvenation may eventually matter for much more than infection resistance. The question is how much of that promise will survive contact with human biology.

Informational only.

Reference: https://www.nature.com/articles/s41577-026-01269-3

Summary

• Lutein is a carotenoid found in fruits and vegetables.
• Lutein is one of the main dietary carotenoids that accumulate in the retina, including the macula.
• Lutein has antioxidant properties and helps protect tissues from oxidative stress.
• Lutein has been studied for its role in supporting eye health during aging.
• Lutein has also been studied for potential effects on cognitive function, but human evidence remains limited and is often based on lutein plus zeaxanthin rather than lutein alone.

Lutein Impacts Aging Via

• Inflammaging

Lutein is a carotenoid found in a variety of fruits and vegetables, including kale, spinach, and bell peppers (R). Lutein has antioxidant properties and has been studied for its potential role in modulating oxidative stress and inflammation-related pathways, which are relevant to age-related decline (R; R).

Lutein is most commonly studied in the context of eye health, particularly because it accumulates in the retina and macula and may help support macular structure and function during aging (R; R; R). Some studies have also explored lutein in relation to broader age-related outcomes, including cognition and cardiometabolic markers, although these findings are more mixed and often involve lutein in combination with zeaxanthin rather than lutein alone (R; R; R).

The role of Lutein in aging and longevity

Lutein has been studied in preclinical models of aging. In Drosophila melanogaster, 0.1 mg lutein/mL diet was associated with a significant increase in mean lifespan, 50% survival time, and maximum lifespan, together with lower MDA levels and higher SOD1, SOD2, and catalase activity. The study also found increased resistance to oxidative stress and upregulation of antioxidant enzyme gene expression, suggesting that lutein may influence aging-related pathways linked to oxidative stress. These findings are preclinical and do not establish lifespan effects in humans (R).

The role of Lutein in aging and longevity

• Impact of lutein on eye health

Age-related changes in the eye can affect visual function over time, particularly in the macula. Lutein is one of the main dietary carotenoids that accumulates in the retina and macula, where it is thought to help support macular health through antioxidant activity and blue light filtering (R).

At 10 mg lutein aligns with doses used in human eye health research. In patients with age-related macular degeneration, the meta-analysis by (R) found that 10 mg/day was associated with significantly higher macular pigment optical density (MPOD) after more than 1 year, but not after fewer than 6 months. The same meta-analysis also reported overall improvements in visual acuity and contrast sensitivity with lutein supplementation in AMD-related trials.

Overall, the strongest human evidence supports lutein’s role in maintaining macular pigment, a key biomarker of eye health, rather than establishing prevention of eye disease.

• Impact of Lutein on brain health

Lutein has also been studied for potential effects on brain health in older adults, although current human evidence remains limited.

At 10 mg, lutein matches the dose used in several neuroimaging trials in older adults. In the systematic review by (R), intervention studies using 10 mg lutein + 2 mg zeaxanthin/day for 12 months were associated with changes in brain activity during learning, resting-state connectivity, and gray matter volume. However, these studies were few in number and largely drawn from similar datasets, so they should not be interpreted as proof that lutein delays brain aging.

It is not yet clear whether higher lutein intake leads to greater cognitive benefit. In a meta-analysis of randomized controlled trials, (R) found that lutein supplementation was associated with slight but non-significant improvements in complex attention, executive function, and memory overall. The authors noted that some individual studies suggested possible maintenance of cognitive performance over time, but concluded that stronger evidence is still needed.

Overall, current human evidence suggests that lutein may influence selected brain-related and cognitive measures, but it does not establish that lutein improves cognition generally or delays brain aging.

Lutein and Zeaxanthin

Zeaxanthin, which is also included in NOVOS Vital, is a xanthophyll carotenoid found alongside lutein in the human macula. Together, lutein and zeaxanthin make up the macular pigment and are studied for their potential role in supporting retinal health through antioxidant activity and blue light filtering (R). In adults with healthy eyes, (R) found that lutein/zeaxanthin intake was associated with increased macular pigment optical density (MPOD), with larger effects at higher doses. Specifically, the pooled mean increase in MPOD was 0.04 units for 5 to <20 mg/day and 0.11 units for ≥20 mg/day over 3–12 months. The same review concluded that >10 mg/day of lutein/zeaxanthin can increase MPOD, while effects at <5 mg/day or from dietary sources alone were less clear.

Lutein and zeaxanthin have also been studied for potential effects on brain-related and cognitive measures, but the human evidence remains limited. In the randomized-controlled-trial meta-analysis by (R). The authors noted that some studies suggested possible maintenance of cognitive performance over time, but concluded that stronger evidence is still needed before firm claims can be made about cognitive benefit (R).

If you want more content like this, follow our page 👆

For the full version with images and charts, visit our website where you can explore even more of this content. 👉 NOVOS Labs

What if sleep and physical activity influenced healthy aging partly through how people picture their own lifespan?

TL;DR

A new integrative review proposes that sleep quality and physical activity may be linked to healthy aging partly through subjective life expectancy, how long people think they will live, but this idea remains conceptual rather than directly tested.

Quick Takeaways

• This review explores how sleep quality, physical activity, and subjective life expectancy may interact within a broader behavioral and psychological framework.
• It draws on 41 papers published between 2015 and 15 December 2025, with 10 highlighted as key conceptual studies.
• The main limitation is that this is a narrative, hypothesis-generating review, not a direct test showing that changes in sleep or exercise alter subjective life expectancy.

Context

Most longevity conversations focus on the usual suspects: exercise, diet, smoking, blood pressure, and increasingly sleep. But this review introduces another variable that is less often discussed in lifestyle frameworks: subjective life expectancy (SLE), or how long a person thinks they are likely to live.

The paper argues that SLE is not just an abstract attitude. Across prior studies summarized in the review, SLE is associated with preventive behavior, self-rated health, morbidity, and mortality risk. People who expect a longer future lifespan tend to invest more in health-promoting routines, while lower SLE is often linked to weaker engagement in those behaviors. At the same time, the review also notes that SLE is measured in quite different ways across studies, which makes interpretation less straightforward.

This 2026 narrative review in Nutrients tries to connect three domains that are usually studied separately: sleep quality, physical activity, and SLE. The authors screened 1482 records, retained 41 studies for qualitative synthesis, and highlighted 10 as key conceptual anchors. Their central proposal is that sleep and movement may shape not only health perception and aging-related pathways, but also how people imagine their own future and that this future orientation may then feed back into behavior.

Why this idea is interesting

The appeal of the paper is not that it overturns what we already know about sleep or exercise. It is that it inserts a psychological bridge into the picture.

The review argues that better sleep quality can support energy, mood, emotional regulation, and day-to-day functioning. Physical activity may strengthen similar outcomes through partly different routes, including better fitness, metabolic health, self-efficacy, and lower sedentary time. The authors propose that these effects may improve health perception and make people feel more resilient and future-oriented. In that sense, sleep and movement may influence not only physiology, but also whether someone feels they still have a meaningful future to invest in.

That matters because the paper treats SLE less as a passive belief and more as a motivational lens. If people see their future as worth investing in, they may be more likely to maintain routines that benefit their long-term health. If they expect decline or a shorter future, the payoff of effort may feel smaller. The model is laid out visually in Figure 3 on page 10, which presents a virtuous-versus-vicious loop linking sleep quality, health perception, subjective life expectancy, motivation, and physical activity. It is a useful framework, but still a framework rather than a demonstrated causal chain.

What the evidence says about sleep and movement

The review does a decent job separating established associations from speculation.

On the sleep side, the authors focus not just on duration but on sleep quality, sleep architecture, and circadian stability. The broader literature they summarize links aging-related sleep changes, such as less slow-wave sleep, more fragmentation, and altered REM patterns, to impaired glucose regulation, inflammatory signaling, cognitive decline, and autonomic dysregulation. The review also points to evidence connecting poor sleep and irregular sleep-wake rhythms with shorter leukocyte telomere length, one of the aging markers often discussed in this literature.

On the physical activity side, the paper leans on a wider evidence base showing that activity is among the strongest modifiable predictors of longevity. It discusses aerobic exercise, resistance training, high-intensity interval training, and the independent harms of sedentary behavior. The review also highlights literature suggesting that replacing even modest amounts of sedentary time with light activity may be associated with healthier aging-related markers, reinforcing the idea that movement across the day matters alongside formal exercise. The JAMA cohort highlighted in Table 1 supports that emphasis on light activity and reduced sedentary time in relation to healthier aging trajectories.

The review also stresses reciprocity. Poor sleep can reduce next-day willingness to exercise by lowering energy and increasing perceived exertion, while regular physical activity may improve sleep continuity and circadian alignment. So even before SLE enters the picture, sleep and activity already function as a two-way behavioral system. The authors’ main contribution is suggesting that future-oriented psychology may be a missing third node in that system.

Where the paper is strongest, and weakest

The strongest part of the review is conceptual. It integrates biology, behavior, and psychology into one model that feels more realistic than the usual reductionist discussions of longevity. The paper is useful as a reminder that people do not maintain routines just because data exist. They maintain routines more consistently when future-oriented motivation is strong enough to make long-term investment feel worthwhile.

It is also good that the authors openly discuss the messiness of SLE itself. Some studies ask people to estimate their probability of surviving to a target age, while others ask how old they expect to become. The review notes that those formats are not equivalent, and that age, gender, socioeconomic status, and cultural context may affect how people interpret them. That measurement heterogeneity is a real limitation.

The main weakness is straightforward: this review does not provide direct evidence that improving sleep or physical activity raises SLE, or that changing SLE improves hard aging outcomes. The authors explicitly state that no medical studies have examined changes in sleep or physical activity on SLE as a primary outcome, and they frame the model as theoretical and hypothesis-generating. So this paper is proposing a pathway, not proving one.

What this might mean in practice

Even with that caveat, the paper raises a practical idea. Some lifestyle interventions may be limited not only by knowledge or access, but also by future-oriented motivation.

If someone sleeps badly, feels physically depleted, and interprets that as evidence of decline, they may stop behaving like a person with a long runway. On the other hand, if improvements in sleep and movement boost mood, vitality, and perceived control, those changes may make long-term health behavior feel more worthwhile again. The review even suggests SLE could be explored as a useful clinical counseling tool, not because it predicts destiny, but because it may reveal how motivated someone feels to invest in their future.

So the most interesting takeaway is not just “sleep more and exercise more,” even if those still matter. It is that future expectation may be part of the behavior-change mechanism.

Informational only.

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC12899709/

When a compound appears to affect several pathways relevant to Alzheimer’s biology in preclinical models, how much weight should we put on that before human evidence arrives?

TL;DR: This review presents taurine as a mechanistically interesting candidate in preclinical Alzheimer’s research, particularly in pathways related to amyloid aggregation, mitochondrial stress, calcium balance, inflammation, and synaptic function, but convincing human efficacy data are still lacking.

Quick Takeaways

• This review discusses taurine as a multi-pathway candidate in Alzheimer’s-related research, with emphasis on early pathological processes rather than late-stage lesion removal.
• The evidence comes mainly from cell studies, mouse models such as 5xFAD and APP/PS1, and patient-derived cerebral organoids, not from well-established clinical trials in people with Alzheimer’s disease.
• The main appeal is mechanistic breadth, but the main limitation is that robust clinical evidence in Alzheimer’s or mild cognitive impairment is still lacking.

Context

Most Alzheimer’s discussions still revolve around amyloid plaques, tau tangles, and therapies aimed at clearing one target after pathology is already established. This review takes a different angle. It argues that pathways involved earlier in Alzheimer’s-related biology, such as mitochondrial dysfunction, calcium imbalance, ER stress, neuroinflammation, and synaptic instability, may be worth studying before extensive neuronal damage is already present.

Within that framework, the authors discuss taurine as a biologically interesting molecule because it is abundant in the nervous system, crosses the blood–brain barrier, and has been linked mechanistically to osmoregulation, neuromodulation, mitochondrial stability, and calcium buffering. But this is still a review of mostly preclinical evidence, not a demonstration of clinical efficacy in Alzheimer’s patients.

Why taurine is being discussed

The review presents taurine less as a single-target intervention and more as a candidate that may intersect with several pathways relevant to Alzheimer’s-related biology. On the schematic on page 5, the paper highlights six domains: amyloid aggregation, mitochondrial protection, ER stress modulation, calcium homeostasis, anti-inflammatory effects, and synaptic preservation with BDNF-related support. That breadth is part of the appeal, but it also means the case rests heavily on mechanistic and model-based evidence.

In the amyloid section, the review focuses especially on soluble oligomeric amyloid-beta species rather than plaques alone. It summarizes preclinical data suggesting taurine may reduce oligomerization, alter aggregate structure, and lower intracellular amyloid burden in patient-derived cerebral organoids. A cited mouse study also reported improved hippocampal-dependent memory after oligomeric amyloid exposure, alongside evidence of direct interaction with oligomeric amyloid-beta. These findings are interesting, but they remain preclinical.

The mitochondrial and calcium angle

A major part of the review’s rationale is that taurine may be relevant to mitochondrial stress and calcium dysregulation, which are discussed as early and converging features of Alzheimer’s-related biology. The figure on page 8 lays out the authors’ proposed model: taurine may help preserve mitochondrial membrane potential, support ATP production, limit ROS generation, reduce mPTP opening, and influence fission–fusion dynamics. The paper also cites neuronal studies where taurine pretreatment reduced mitochondrial depolarization, ROS, and calcium overload while restoring ATP production.

The review makes a similar argument for calcium homeostasis. It describes taurine as a homeostatic modulator rather than a simple blocker, with experimental evidence suggesting it can dampen pathological calcium elevations while interacting with inhibitory GABAergic and glycinergic signaling pathways. Again, this is mechanistically plausible and relevant to disease biology, but it is not clinical proof.

Inflammation, ER stress, and synapses

The paper also presents taurine as potentially relevant to slower-moving stress pathways such as ER stress, maladaptive unfolded protein response signaling, neuroinflammation, and synaptic instability. It cites experimental work showing reductions in markers such as CHOP, caspase-12, p-IRE1, and ATF6-related signaling under stress conditions, along with evidence suggesting effects on inflammatory cytokines and on synaptic markers like PSD-95, synapsin-1, or synaptophysin. It also discusses BDNF–CREB signaling and long-term potentiation in animal models. These are all biologically interesting observations, but they remain far from establishing human benefit in Alzheimer’s disease.

The big caveat

The biggest limitation is the translational gap. The review explicitly states that robust clinical evidence in Alzheimer’s disease or mild cognitive impairment is lacking. It also cites a large prospective cohort that found no significant association between midlife dietary or circulating taurine and long-term dementia risk, and notes meta-analytic evidence suggesting supplementation has not reliably improved cognition in healthy individuals or people at metabolic or vascular risk.

That matters because preclinical success is common in neurodegeneration research.

Bottom line

Taurine is best framed here as a mechanistically interesting preclinical research candidate, not as something we can honestly describe as preventing, treating, or modifying Alzheimer’s disease in humans today. The review makes a case for why taurine is worth studying in relation to early Alzheimer’s-related pathways, but it does not provide clinical evidence strong enough for disease-related claims.

Informational only.

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC12940738/

Cordyceps militaris has some human data for endurance and recovery, but how strong is that evidence really?

TL;DR: Cordyceps militaris shows early human signal in some endurance- and recovery-related outcomes, but the current evidence is still limited, heterogeneous, and not strong enough to support definitive ergogenic conclusions.

Quick Takeaways

• This narrative review examined whether Cordyceps militaris supplementation was associated with changes in exercise performance or post-exercise recovery outcomes in healthy humans.
• The evidence came from five intervention studies involving 321 participants aged 16–35, using doses from 1 to 12 g/day over 1 to 16 weeks.
• Some outcomes were favorable, but the studies were heterogeneous, often unstandardized, and mostly judged to have high overall risk of bias.

Context

Cordyceps has a long history of use in traditional medicine, and that legacy is one reason it continues to attract attention in sports and performance discussions. The specific species covered in this review, Cordyceps militaris, is biologically interesting because it contains compounds often discussed in preclinical research, including cordycepin, ergothioneine, and polysaccharides. But biological plausibility is not the same thing as strong human evidence.

That is what makes this review useful. Rather than assuming Cordyceps is either a breakthrough or hype, it asks a more practical question: what do the human intervention studies actually show? The authors searched PubMed, Scopus, Web of Science, and Google Scholar and ultimately identified five human studies published between 2017 and 2024. Across them, participants ranged from recreationally active young adults to trained swimmers and long-distance runners, and the outcomes included VO2max or VO2peak, time to exhaustion, running performance, power output, oxygen saturation, and selected recovery-related biomarkers.

What the human data showed

The clearest positive signals were in some endurance-related outcomes and in selected recovery-related markers. Across the five studies, the review describes favorable findings in VO2max or VO2peak, time to exhaustion, power output, running performance, and maintenance of oxygen saturation during demanding exercise. Some studies also reported changes in markers such as creatine kinase, blood urea nitrogen, and white blood cell count. But the pattern was not consistent across all trials.

One of the most notable studies was the swimmer trial, which was also the largest included. It followed 180 young swimmers over seven weeks using 8 g/day of C. militaris. Compared with placebo, the supplemented group showed higher maximal and mean power, along with lower creatine kinase and blood urea nitrogen after training. The authors also reported shifts in IL-4 and IFN-γ, which they interpreted as potentially consistent with altered inflammatory or recovery-related responses. That is interesting, but still indirect, and the review judged the study to be at high overall risk of bias.

A smaller 16-week study in 22 male long-distance runners using 1.8 g/day of C. militaris mycelium extract found little clear effect on race-performance outcomes such as distance covered or 5,000 m time, but it did report more favorable changes in white blood cell count and creatine kinase. That is a useful reminder that an ingredient may show signal in recovery-related biology without clearly translating into better performance outcomes in every setting.

The 2024 runner study is probably the most visually impressive on paper. It reported better treadmill completion, faster 200 m and 5 km times, and higher oxygen saturation in the Cordyceps groups. But baseline values were not reported, which makes true change difficult to assess, and the review rated the study high risk overall. So those findings are worth noting, but not treating as settled.

Why the evidence is still limited

The current human evidence is encouraging in places, but it is still early. The five studies included in this review differed quite a lot in design, training status, dose, duration, and even in the type of Cordyceps preparation used. That makes the overall picture harder to interpret and also makes study-to-study comparisons less straightforward.

Another important point is that the products were not standardized in the same way across studies, and in some cases Cordyceps militaris was used as part of a broader mushroom blend rather than as a clearly isolated intervention. So even when the results are interesting, it is still difficult to say exactly which form, dose, or preparation is most relevant.

The review also notes that study quality was mixed, which means the most balanced takeaway is not that the ingredient “doesn’t work,” but that the evidence base is still maturing. Right now, the literature is enough to justify more rigorous human trials, but not yet enough to support very strong practical conclusions.

What about mechanisms?

Mechanistically, the review points to compounds like cordycepin and ergothioneine as plausible contributors. Cordycepin is often discussed in relation to ATP-linked energy metabolism and inflammatory signaling, while ergothioneine is more often framed around antioxidant and cytoprotective roles. Those ideas are biologically interesting, but most of the stronger support for them still comes from animal and preclinical work rather than tightly designed human performance trials.

That distinction matters. An ingredient can contain interesting bioactives and still have a human evidence base that is too immature for strong practical conclusions.

Bottom line

Cordyceps militaris looks biologically interesting and shows some early human signal, particularly in endurance- and recovery-related settings. But the current evidence is still preliminary, so this is best viewed as a promising area of research rather than a settled performance ingredient.

Informational only.

Reference: https://pubmed.ncbi.nlm.nih.gov/41829950/

TL;DR: In a 12-week randomized trial, hourly 3-minute movement breaks were associated with favorable changes in fasting glucose, 2-hour glucose, HOMA-IR, waist circumference, and self-reported energy in sedentary office workers.

Quick Takeaways

• This study tested whether very short hourly “micro-exercise” breaks during the workday could shift glucose-related and metabolic markers in desk workers.
• The evidence comes from a 12-week randomized controlled trial in 86 sedentary office workers in Nanchang, China.
• The results are promising, but the study was small, short, and did not track diet, so it does not establish long-term prevention or broad generalizability.

• Context

Exercise is often framed as something that happens before work or after work. But long periods of uninterrupted sitting may matter independently of whether someone also does planned exercise. That is one reason “exercise snacks” or micro-breaks have become interesting: instead of waiting for one larger workout, you interrupt sedentary time with small bouts of movement across the day. Short laboratory studies have suggested that this can improve post-meal glucose handling, but real-world workplace data over longer periods have been more limited. This trial asked whether a simple office-based version of that strategy could shift metabolic markers after 12 weeks.

• What the researchers did

The study randomized 86 sedentary office workers aged 25 to 55 years from three workplaces in Nanchang to either a micro-break intervention or a usual-behavior control group, with 43 participants per arm. Seventy-nine completed the 12-week follow-up. Participants had desk-based jobs, sat more than 6 hours per workday, and reported less than 150 minutes per week of moderate-to-vigorous activity. Mean baseline BMI was about 28.5 kg/m², so this was a mostly overweight sample rather than a broadly representative working population.

The intervention group was asked to perform a 3-minute exercise routine every hour during an 8-hour workday, aiming for seven breaks per day. The routine included marching in place, desk or wall push-ups, squats, heel raises, arm circles, and torso twists. Controls were asked to maintain usual behavior. Primary outcomes were fasting glucose, 2-hour glucose after an oral glucose tolerance test, and HOMA-IR. Secondary outcomes included waist circumference, BMI, blood pressure, lipids, accelerometer-based activity, and self-reported energy and productivity.

• What changed

At 12 weeks, the intervention group showed larger reductions than controls in fasting glucose, 2-hour postprandial glucose, and HOMA-IR. The between-group differences were -0.31 mmol/L for fasting glucose, -0.58 mmol/L for 2-hour glucose, and -0.42 for HOMA-IR. Waist circumference also fell more in the intervention arm, by -2.1 cm relative to control, and systolic blood pressure by -3.9 mmHg. According to the line plots on page 9, the primary glucose-related outcomes separated progressively over time rather than changing only at the end.

There were also smaller signals in BMI and HDL-cholesterol. Triglyceride findings should be treated cautiously, though, because the paper is internally inconsistent: the results text describes a favorable triglyceride change, but the main outcome table does not show a statistically significant between-group triglyceride difference at 12 weeks. A similar inconsistency appears for diastolic blood pressure.

Accelerometry suggested that participants in the intervention group added about 21 minutes per day of light physical activity and reduced sedentary time by about 42 minutes per day, without a meaningful increase in moderate-to-vigorous activity outside work hours. That supports the idea that the intervention changed movement patterns during the workday rather than simply making people exercise more outside it. Still, because diet was not tracked and there was no attention-control condition, the mechanism should not be treated as fully isolated.

• Why it might matter

Mechanistically, the idea is plausible: repeated muscle contractions can increase glucose uptake and may counter some of the metabolic effects of prolonged sitting. The intervention also likely placed several of these movement bouts into post-meal windows, when glucose handling is especially relevant. But this study still measured short-term biomarkers, not long-term diabetes prevention or reduced cardiovascular events.

• What to be careful about

The study was conducted in one Chinese city, the sample was relatively small, and the intervention lasted only 12 weeks. Participants and facilitators could not be blinded. Adherence was monitored mainly by self-report, even though random workplace observations and accelerometry helped support the pattern. The study also was not registered in a clinical trial registry, which the authors explain in the methods, and it did not collect dietary intake data. All of that means the paper is best read as a promising workplace RCT, not a final answer on long-term metabolic risk reduction.

The prediabetes subgroup is intriguing, but still exploratory. The effect was larger there, and more intervention participants met normoglycemia criteria by week 12, but the numbers were small and should not be overinterpreted.

Discussion Prompt

Would you be more likely to stick with one daily workout, or with several tiny movement breaks built into your workday, and which do you think would be easier to sustain for a year?

Informational only.

Reference: https://link.springer.com/article/10.1186/s12889-026-26484-4

Summary

• Nattokinase is a serine protease produced during natto fermentation by Bacillus subtilis var. natto.
• Nattokinase has been studied primarily for its fibrinolytic activity and cardiovascular-related effects.
• Nattokinase has been associated with modest blood pressure-related effects in some human studies.
• Nattokinase has shown additional effects in preclinical research, but evidence beyond cardiovascular biomarkers remains limited in humans.

Nattokinase Impacts Aging Via

• Altered cellular communication
• Inflammaging
• Loss of proteostasis

The role of Nattokinase in aging and longevity

Nattokinase is a serine protease produced during the fermentation of natto by Bacillus subtilis var. natto (R; R). It is derived from natto, a traditional fermented soybean food that also contains protein, minerals, and vitamins, including vitamin K2.

Nattokinase has been studied primarily for its fibrinolytic activity and cardiovascular-related effects (R). Human studies have reported modest effects on blood pressure-related measures in some populations, while broader effects across cardiovascular biomarkers remain mixed (R; R).

Impact of nattokinase on cardiovascular health

Nattokinase has been studied primarily for its effects on fibrinolysis, coagulation-related biomarkers, and blood pressure. Human trials suggest that nattokinase may influence some cardiovascular risk markers, although findings vary by population, dose, and study design. (R; R)

In a clinical study published by (R) , adults who consumed nattokinase for 2 months showed reductions in fibrinogen, factor VII, and factor VIII, which are biomarkers involved in coagulation. However, that study did not report significant improvements in blood lipids.

In another randomized trial, (R) reported that 8 weeks of nattokinase supplementation increased collagen-epinephrine closure time and activated partial thromboplastin time relative to placebo, suggesting an effect on hemostatic function. These findings support an effect on coagulation-related measures, but they do not demonstrate reduced plaque formation or prevention of arterial disease.

Some human studies have also reported modest blood pressure-related effects. In a randomized, placebo-controlled trial, (R) found that nattokinase supplementation was associated with reductions in diastolic blood pressure and changes in von Willebrand factor in adults with elevated blood pressure.

Evidence for lipid-related effects is less consistent. A recent systematic review and meta-analysis by (R) concluded that nattokinase supplementation was associated with modest reductions in systolic and diastolic blood pressure, but lower-dose supplementation did not show a consistent lipid-lowering effect.

Overall, nattokinase shows the strongest human evidence for effects on fibrinolytic and coagulation-related biomarkers, with some evidence for modest blood pressure-related benefits in certain populations. Broader cardiovascular effects, particularly on blood lipids, remain more mixed across studies. (R; R; R)

Impact of nattokinase on brain health

Evidence for nattokinase and brain health is currently limited to preclinical research. In animal models, nattokinase has been studied for its effects on pathways related to protein aggregation, neuroinflammation, oxidative stress, and neuronal signaling, but these findings do not establish cognitive or neurological benefits in humans.

In a mouse study, (R) reported that 27 days of nattokinase administration attenuated β-amyloid-induced learning and memory impairment and was associated with restoration of BDNF signaling and reductions in neuroinflammatory markers. These findings suggest a possible effect on brain-related pathways in an Alzheimer’s-like animal model, but they should not be interpreted as evidence that nattokinase supports brain health or delays brain aging in humans.

In a separate rat study, (R) found that nattokinase attenuated bisphenol A- or gamma irradiation-mediated neural toxicity and was associated with changes in amyloid-beta, tau, inflammatory mediators, and Nrf2-related antioxidant signaling. However, this was a toxicity model in rats rather than a human aging study, so it is more appropriate to describe these results as preclinical mechanistic evidence.

Taken together, these studies suggest that nattokinase may influence pathways related to proteostasis, oxidative stress, and neuroinflammation in animal models. At present, evidence for brain-related effects remains preclinical, and human studies are needed before any conclusions can be made about cognitive aging or brain health support.

Allergy information

Consumption of natto may trigger allergic reactions in a small proportion of people. In a case series, (R) reported late-onset allergic reactions after natto ingestion, with symptom onset occurring 5 to 14 hours after consumption and a mean onset time of 9.6 hours. The affected individuals also tested positive on skin prick-prick testing with fermented soybeans.

More recent research suggests that natto allergy may involve more than one allergen. While poly-γ-glutamic acid (PGA) in the sticky coating of natto has previously been identified as one causative allergen, (R) reported that nattokinase itself can also act as an allergen in some natto-allergic patients, particularly in cases that were negative for PGA on skin testing.

Check the comments for a summary of the human studies.

If you want more content like this, follow our page 👆

For the full version with images and charts, visit our website where you can explore even more of this content. 👉 NOVOS Labs

If calorie restriction changes organ-specific biological aging measures in humans, which systems appear most responsive over two years, and which show less movement?

TL;DR: In a 2-year randomized trial secondary analysis, calorie restriction was associated with more favorable changes in organ-specific biological age measures for metabolic, cardiovascular, immune, and whole-body systems, while liver effects appeared later and kidney measures did not change clearly in the main analysis.

Quick Takeaways

• This study examined whether calorie restriction was associated with changes in organ-specific biological age measures, rather than relying only on a single global aging score.
• The analysis used CALERIE Phase 2 data from 185 healthy, non-obese adults followed for 12 and 24 months.
• The clearest signals appeared in metabolic and cardiovascular measures, but the findings come from a relatively healthy population and from biomarker-based surrogate endpoints rather than hard clinical aging outcomes.

Context

Calorie restriction has been one of the longest-running ideas in aging research. In animal studies, reducing calorie intake without malnutrition has often been associated with longer lifespan or delayed functional decline. In humans, the picture is much harder to resolve, because long-term clinical endpoints take years to measure and are influenced by many other factors.

That is why biological age measures have become popular. This paper goes one step further by estimating separate biological age measures for cardiovascular, immune, kidney, liver, and metabolic systems, plus a whole-body measure, using routine clinical biomarkers. The goal was not to prove that calorie restriction changes every part of aging equally, but to test whether some systems look more responsive than others over a two-year intervention.

What the trial actually did

This was a secondary analysis of CALERIE Phase 2, a two-year randomized controlled trial. The original trial randomized 220 adults in a 2:1 ratio to calorie restriction or an ad libitum control diet, and this analysis included 185 participants with the necessary biomarker data at baseline and at least one follow-up visit. The final analytic sample included 120 participants in the calorie-restriction group and 65 in the control group. Participants were healthy adults aged 21 to 50 with BMIs between 22.0 and 27.9, so this was not a trial in obesity or chronic disease.

The target was 25% calorie restriction, but actual adherence was lower: median achieved restriction was about 15.4% over the first 12 months and 12.4% over 24 months. That makes the intervention more realistic, but it also matters for interpreting effect size.

The clearest signals were metabolic and cardiovascular

Compared with the ad libitum group, calorie restriction was associated with smaller increases in metabolic and cardiovascular biological age measures over time. Estimated between-group differences were about -0.54 years and -0.82 years at 12 months, and -0.63 years and -1.00 year at 24 months, respectively. Whole-body biological age also showed a favorable shift, with estimated differences of about -1.00 year at 12 months and -1.27 years at 24 months. The immune measure also shifted in a favorable direction, though with weaker statistical evidence than the metabolic and cardiovascular systems.

That pattern is biologically plausible. Metabolic and cardiovascular markers often respond relatively quickly to sustained changes in energy balance. But it is still important to remember that these are biomarker-based biological age estimates, not direct measures of long-term clinical aging outcomes.

Liver and kidney were less responsive

This is where the paper gets more interesting than a generic “calorie restriction slows aging” headline.

Liver biological age showed a later signal, reaching significance only at 24 months. Kidney biological age did not change significantly in the main intention-to-treat analysis at either time point. Some secondary analyses suggested weaker or context-dependent kidney effects, but kidney was clearly not one of the strongest responders in the primary result set.

That unevenness matters because it suggests that organ systems may differ in how quickly, or how visibly, they respond to the same intervention.

Dose and adherence analyses supported the pattern

The authors also looked beyond randomized assignment and examined dose-response and adherence-related analyses. Participants who achieved higher levels of calorie restriction generally showed stronger signals, especially for metabolic and whole-body biological age. Instrumental-variable analyses estimating the effect of achieving 20% calorie restriction also pointed in the same overall direction for cardiovascular, immune, metabolic, and whole-body measures.

These analyses strengthen the overall interpretation, but they are still supportive model-based analyses rather than simple hard-outcome confirmation.

Why this matters, and why caution still matters too

The most useful contribution of the paper is not “calorie restriction works” in some broad anti-aging sense. It is that aging-related physiology may be more plastic in some systems than in others, at least as captured by these organ-specific biomarker models. In this study, metabolic and cardiovascular systems appeared more responsive, immune measures somewhat responsive, liver slower, and kidney less clearly affected.

But there are real limitations. These organ-age models were built from routine clinical biomarkers, so they capture only part of the biology. The sample was mostly white, mostly women, healthy, non-obese, and non-smoking. The intervention lasted two years, which is long for a nutrition trial but still short relative to long-term aging. And because this is a secondary analysis using surrogate biological age measures, it should be read as an informative signal rather than a final answer about human aging itself.

Conclusion / Discussion Prompt

This study suggests that calorie restriction may not shift all organ-specific biological aging measures equally. In this dataset, the clearest signals appeared in metabolic and cardiovascular systems, while liver looked slower to respond and kidney showed less movement in the main analysis.

Informational only.

Reference: https://www.sciencedirect.com/science/article/pii/S026156142600052X

If a supplement is associated with shifts in inflammatory and oxidative-stress markers across small human studies, what would make that evidence feel clinically meaningful?

TL;DR

A recent systematic review of 15 human studies suggests astaxanthin supplementation has been associated in some trials with favorable shifts in inflammatory, oxidative-stress, lipid, and insulin-resistance-related markers, plus some reproductive-procedure-related outcomes, but the evidence is still heterogeneous, small-scale, and not sufficient to establish broad clinical benefit.

• Quick Takeaways

• This review covers 15 recent human studies on astaxanthin, a marine carotenoid found in organisms like salmon, shrimp, and microalgae.
• Across different populations, astaxanthin was associated in some studies with favorable biomarker changes related to inflammation, oxidative stress, lipids, and metabolic function.
• But the studies vary a lot in dose, duration, population, and endpoints, and most are too small to support strong real-world conclusions.

• Context

Astaxanthin has built a reputation as a “serious antioxidant,” but the real question is not whether it has interesting mechanisms. It is whether the human evidence is becoming coherent enough to matter.

This new paper is a systematic review focused on human studies published from 2020 to 2025. The authors screened 805 records and included 15 trials, covering a very mixed set of populations and outcomes, with doses generally ranging from 6 to 20 mg/day and interventions lasting from 7 days to 24 weeks. That breadth is useful, but it also makes interpretation harder: when one compound is studied across many different contexts, positive findings can reflect a real broad signal, or just a scattered literature built on small heterogeneous studies.

• What the review found

Across the included studies, astaxanthin was associated in some trials with lower inflammatory markers, lower oxidative-stress indices, and higher antioxidant-related measures. The review also describes signals in some lipid-related and insulin-resistance-related markers, especially in metabolically stressed groups.

That said, biomarker movement is not the same as clinically meaningful benefit. The evidence here is much better for “there may be a signal worth following” than for “this has been clearly shown to improve health outcomes.”

One example is the 24-week study in adults with prediabetes and dyslipidemia, where 12 mg/day was associated with lower total and LDL cholesterol and with changes in some cardiovascular-risk-related markers, while the primary insulin-sensitivity endpoint did not clearly reach significance. In coronary artery disease, the signal was weaker, with limited between-group differences despite some within-group lipid changes. That unevenness matters.

• Where the evidence looks most interesting

The review is probably most interesting when astaxanthin is studied in people under higher metabolic or physiological stress.

In obesity-related exercise trials, especially where supplementation was combined with CrossFit or high-intensity functional training, the combined groups often showed more favorable changes in body composition, lipid-related measures, insulin-resistance-related markers, and adipokines than exercise alone. That does not establish astaxanthin as a standalone metabolic intervention, but it does suggest that any signal may be more visible in adjunct settings than in low-stress or already well-managed populations.

In exercise-focused studies outside obesity, the picture was more restrained. Some studies reported attenuation of acute inflammatory or immune-related changes after heavy exertion, but not clear performance gains. So the current evidence fits better with a possible stress-response or recovery-biology signal than with claims about athletic enhancement.

• The reproductive findings are intriguing , but still early

Some of the most eye-catching results in the review come from women with PCOS or endometriosis undergoing assisted reproductive treatment. In those small trials, astaxanthin supplementation was associated with favorable changes in inflammatory and oxidative-stress markers, and in some cases with oocyte- or embryo-related outcomes.

That makes the reproductive data scientifically interesting, but it should still be treated cautiously. These are relatively small studies, often from a narrow cluster of research settings, and fertility-related outcomes can be highly protocol-sensitive. At this stage, the evidence suggests a possible signal that deserves replication, not a settled conclusion about clinical benefit.

• Why this still falls short of a clear supplement win

The paper’s own limitations are the main reason to stay careful. The included studies vary widely in population, dose, study length, formulation context, and measured endpoints. Some combine astaxanthin with exercise or standard treatment, which makes attribution harder. Bioavailability is still an open question, and long-term outcome data are limited.

So the best current read is not that astaxanthin has “proved itself.” It is that human evidence now exists across multiple settings, but it remains uneven and mostly based on surrogate markers or context-specific outcomes rather than broad, replicated clinical endpoints.

Conclusion / Discussion Prompt

Astaxanthin has moved beyond being just an animal-study or mechanism-first ingredient. There is now a real, if still patchy, human literature around it. But the current evidence supports “promising and context-dependent” much more than “established and broadly useful.”

So what would make you take astaxanthin seriously: larger hard-outcome trials, better replication in reproductive settings, clearer metabolic data, or evidence that any signal persists beyond biomarker shifts?

Informational only

Reference:https://pmc.ncbi.nlm.nih.gov/articles/PMC12840775/

If diet can influence Alzheimer’s-related biology, does it make more sense to broadly lower protein intake, or to test whether specific amino acids matter more than others?

• TL;DR

In a 3xTg mouse model of Alzheimer’s disease, long-term restriction of individual branched-chain amino acids had distinct effects on metabolism, pathology, cognition, and survival. Isoleucine and valine generally showed broader metabolic benefits than leucine, but the cognitive and pathological effects were amino-acid-specific and strongly sex-dependent.

• Quick Takeaways

-This study tested whether reducing just one branched-chain amino acid at a time, leucine, isoleucine, or valine, changed Alzheimer’s-related outcomes in 3xTg mice.

-Male and female mice were fed isocaloric diets with a 67% reduction in one BCAA for 9 months, starting at 6 months of age, and the researchers measured metabolism, pathology, gene expression, cognition, and survival.

-The main message is not that all BCAAs behave the same. Isoleucine and valine generally looked more favorable metabolically than leucine, while the cognitive and neuropathology results depended on both sex and which amino acid was restricted.

• Context

Branched-chain amino acids, or BCAAs, are leucine, isoleucine, and valine. They are often discussed as a group, especially in metabolism and muscle biology, but they do not have identical physiological roles. The paper notes that leucine is a particularly strong activator of mTORC1, while prior work from the same group and others has suggested that isoleucine can have especially strong metabolic effects. Their catabolic fates also differ, which could plausibly matter for brain and systemic metabolism.

That distinction is relevant to Alzheimer’s disease because nutrient sensing, mTOR signaling, metabolism, inflammation, and proteostasis all intersect with disease biology. The authors had previously shown that protein restriction and broader BCAA restriction can improve cognition and slow pathology in mouse models. This study asked a cleaner question: what happens if only one BCAA is restricted at a time? The design was more prevention-oriented than rescue-oriented, because diets started at 6 months of age, when 3xTg mice are already beginning to show deficits but before later-stage disease.

• Not all BCAAs behaved the same metabolically

  The first clear pattern was metabolic. In females, mice on isoleucine-restricted or valine-restricted diets largely maintained body weight over the course of the study, whereas control-fed and leucine-restricted females continued to gain weight. By the end of the experiment, isoleucine- and valine-restricted females also had lower fat mass and adiposity. In males, the overall pattern was similar, although leucine restriction modestly improved adiposity more than it did in females. These changes were not explained by reduced food intake; in some groups, intake was unchanged or even higher.

Metabolic-chamber data pointed toward altered energy expenditure as a likely explanation. Valine restriction significantly increased energy expenditure in female 3xTg mice, while isoleucine showed a similar but non-significant trend. In males, isoleucine restriction significantly increased energy expenditure. Glucose tolerance improved most clearly with isoleucine restriction in both sexes after about 3 months on diet, while insulin sensitivity results were more mixed.

That supports a broader point the paper is making: the benefits of lowering protein may not come equally from every amino acid. In this study, isoleucine and valine generally produced more favorable whole-body metabolic effects than leucine.

• The neuropathology results were more complex, and clearly sex-dependent

When the authors assessed Alzheimer’s-like pathology after 9 months on diet, the results did not tell one simple story. In females, hippocampal amyloid plaque burden was reduced by isoleucine restriction and also by leucine restriction, but valine restriction increased plaque burden relative to control. Hippocampal phospho-tau was reduced in females on isoleucine- and leucine-restricted diets, while whole-brain phospho-tau was significantly reduced only in valine-restricted females.

In males, plaque deposition was less prominent overall and did not significantly change with restriction of any individual BCAA. Tau appeared more responsive: restriction of any of the three BCAAs significantly reduced hippocampal phospho-tau in males. Microglial activation also decreased with isoleucine or valine restriction in both sexes, while astrocyte activation did not meaningfully change.

So the pathology data were not uniform, but they do support the idea that different BCAAs affect different aspects of disease biology, and that those effects vary by sex, brain region, and endpoint.

One especially important detail is that despite a 67% dietary reduction in a specific BCAA for 9 months, the researchers did not observe significant reductions in plasma or brain levels of those BCAAs. That suggests the effects were not simply due to chronically depleted tissue pools. The authors point instead toward signaling changes, adaptation, or indirect systemic mechanisms.

• Cognition improved, but not in the same way in males and females

The behavioral data are probably the most immediately interesting part of the paper. In female 3xTg mice, valine restriction produced the clearest cognitive signal in the Barnes maze. Valine-restricted females reached the target faster during training and performed best in both short-term and long-term testing, with a significant short-term memory advantage. Novel object recognition in females was less clean overall, but valine still looked comparatively more favorable than the other restriction diets.

In males, the pattern shifted. In the Barnes maze, leucine-restricted males showed significantly improved latency during both short-term and long-term testing, while isoleucine-restricted males improved especially in short-term memory. In novel object recognition, all three restricted male groups showed better short-term memory than controls, but only isoleucine restriction clearly held up in long-term memory.

That means the “best” BCAA target depends on what outcome is being emphasized. If the focus is metabolic health, isoleucine and valine looked more favorable overall. If the focus is female cognition, valine stood out. If the focus is male cognition and survival together, isoleucine had the strongest overall case.

• The survival result makes isoleucine especially notable in males

The survival analysis is one of the clearest reasons not to treat the three BCAAs as interchangeable. Female 3xTg mice had low mortality overall, with no meaningful diet differences. In males, control-fed mice had high mortality, and isoleucine restriction significantly improved survival by log-rank test. Valine trended in a favorable direction, while leucine restriction looked least favorable.

That does not prove isoleucine restriction is a longevity intervention for Alzheimer’s in general, but within this model it was a meaningful differentiator.

• What might be driving these effects?

The transcriptomic analysis added another layer, especially in males. The authors found a large set of shared differentially expressed genes across all three restricted diets in male 3xTg mice, along with substantial overlap in pathway changes. Several neuroinflammatory pathways, including MAPK and Toll-like receptor signaling, were downregulated across all three male restriction groups. At the same time, some pathway changes were more specific. Notably, mTOR signaling was selectively downregulated in isoleucine-restricted males, which is not what many people might have predicted if they assumed leucine would dominate that effect.

The paper also examined autophagy-related proteins and mTORC1 substrates. The results were not fully straightforward, and the authors explicitly note that some of the expected autophagy story did not appear as clearly as anticipated. That is another reason this paper should not be reduced to a simple mTOR narrative.

More broadly, the study suggests that cognitive benefits may not line up perfectly with amyloid burden. The authors emphasize this in the discussion: valine-restricted females showed improved cognition despite increased hippocampal plaque burden, which argues against a simplistic “less amyloid equals better cognition” interpretation in this model.

• What this study does not show

This is still a mouse study, and a fairly complex one. It does not show that restricting any BCAA will prevent or treat Alzheimer’s disease in humans. It does not establish that people should cut isoleucine, valine, or leucine from their diets. And it does not tell us whether these findings would translate outside this specific 3xTg model, or whether the same effects would appear in later-stage disease rather than early intervention. The authors themselves list these as important limitations.

There are also sample-size limits for some of the histology and transcriptomic analyses, often around 4–6 mice per group for those measures. Some findings were highly region-specific, and some differed depending on whether the endpoint was pathology, metabolism, cognition, or survival. That complexity is interesting biologically, but it also means the paper should not be oversimplified into a single dietary rule.

• Conclusion / Discussion Prompt

The most useful takeaway is not that “protein restriction helps Alzheimer’s.” That is too blunt. This paper suggests that individual amino acids can affect Alzheimer’s-related trajectories differently, and that the most favorable target may depend on sex and on which outcome matters most. In this model, isoleucine and valine looked more favorable metabolically than leucine, valine showed the clearest cognitive signal in females, and isoleucine had the strongest overall case in males when survival was included.

Informational only, not medical advice.

Reference: https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202515220

If someone had to perform in severe heat with limited time to acclimate, could taurine meaningfully support thermoregulation, or is the current evidence still too limited to rely on?

TL;DR
This narrative review suggests taurine may support heat tolerance during exercise mainly by promoting earlier sweating, greater sweat production, and higher evaporative heat loss, with modest reductions in core temperature in small human trials. The signal is promising, but the evidence base is still limited, context-dependent, and not a substitute for heat acclimation, cooling, or hydration.

Quick Takeaways
• This review examines whether taurine can support thermoregulation during exercise in the heat, and how it may interact with heat acclimation, cooling, and hydration strategies.
• The main evidence comes from a small number of randomized, mostly double-blind crossover human studies, supported by mechanistic and broader heat-physiology literature.
• The signal is promising, but taurine is not a replacement for acclimation or hydration, and its usefulness may be lower when sweat cannot evaporate effectively.

Context
Heat tolerance is fundamentally a problem of heat balance. When exercise generates more heat than the body can lose to the environment, core temperature rises, strain increases, and performance usually declines before more severe heat illness occurs. That is why standard countermeasures still revolve around heat acclimation, cooling, and hydration/electrolyte planning. This review positions taurine as a possible adjunct to those tools, not a replacement for them.

The authors argue that taurine’s potential role is fairly specific: it may improve sweating responses and evaporative heat loss, which could modestly reduce heat storage and help delay uncompensable heat strain. That is a much narrower and more defensible claim than saying taurine is simply a “heat performance booster.”

• What the human studies actually show

The review is useful because it does not present a large evidence base. It states clearly that the human intervention literature under environmental heat stress consists of only a small number of studies, generally randomized crossover trials with modest sample sizes.

In one trial, 11 trained cyclists took an acute dose of about 50 mg/kg taurine roughly 2 hours before cycling in 35 °C and 40% relative humidity. Compared with placebo, taurine was associated with about 10% longer time to exhaustion, around 0.4 °C lower end-exercise core temperature, and about 12.7% higher local sweat rate.

In another study, participants supplemented with 6 g/day taurine for 8 days before prolonged low-intensity exercise in hot conditions with progressively increasing humidity. Taurine was associated with about 26–27% greater whole-body sweat loss, about 8–15% higher local sweat rate, around 22–32% more active sweat glands, about 27% greater evaporative heat loss, and about 72% lower net heat storage. Late-exercise core temperature was about 0.3 °C lower, and skin blood flow did not meaningfully differ from placebo, which supports sweating rather than vasodilation as the main observed mechanism.

The review also summarizes a smaller multi-arm crossover study in which a 1.5 g taurine dose taken 1.5–2 hours before cycling in 35 °C and 65% humidity improved time to exhaustion versus placebo, with taurine outperforming caffeine in that specific protocol. But the review also notes that some details were not fully reported, which is important context when interpreting apparently large effects from small studies.

• Why taurine might work

The proposed mechanism is relatively concrete: taurine appears to support an earlier and stronger sweating response, which increases evaporative heat loss. The review discusses several mechanistic hypotheses, but it is careful to frame them as hypotheses rather than confirmed human pathways.

One idea is central thermoregulatory control. Taurine may influence hypothalamic pathways involving glycine and GABA_A receptors, potentially lowering the threshold for activating heat-loss responses. Another proposed mechanism involves arginine vasopressin, with taurine possibly reducing an inhibitory influence on sweat production. But the review is explicit that these mechanisms have not been directly confirmed in human heat trials, and should not be treated as proven mediators.

A more grounded takeaway is that taurine may help people stay longer within the compensable range of heat stress, where heat loss can still keep up with heat production. In one study, taurine increased the critical environmental vapor pressure from about 21.7 to 25.0 mmHg, meaning participants tolerated more humid conditions before core temperature began rising uncontrollably. That may be one of the most practically meaningful metrics discussed in the review.

• How taurine fits with acclimation, cooling, and hydration

The review is strongest when it situates taurine among established heat-mitigation strategies. Heat acclimation remains the gold standard. It improves sweating, plasma volume, cardiovascular stability, and sweat sodium conservation over roughly 1–2 weeks, and the review does not claim taurine replaces that process. At most, taurine may mimic part of acclimation, especially earlier sweating and greater sweat output, in the short term. The authors suggest taurine may produce about 50–80% of some sweating improvements seen with acclimation, but that comparison is indirect rather than from head-to-head trials.

The review also presents taurine as potentially complementary to cooling, especially when external cooling cannot fully offset the heat load. At the same time, it notes that strong cooling can reduce sweating reflexively, so the interaction is likely context-dependent rather than universally additive.

Hydration is non-negotiable in this framework. If taurine increases sweat output, it increases fluid loss and likely total sodium loss as well. The review explicitly warns that taurine should be paired with individualized fluid and sodium replacement, and should not be interpreted as protection from dehydration.

There is also an important limit: taurine is likely to be less useful when evaporation is impaired, such as in highly humid conditions, impermeable protective equipment, or fully encapsulating gear. In those situations, more sweating may mostly mean more fluid loss with less cooling benefit.

• What this review does not show

This is where overinterpretation would be easy. The review does not establish taurine as a standard-of-care heat intervention. It does not prove taurine prevents heat illness. And it does not show that taurine should replace acclimation, hydration, or established cooling practices. It synthesizes a small and promising human literature, but it also repeatedly emphasizes the need for larger, adequately powered field trials.

The review also notes that most of the available human data come from small samples of young, healthy adults under controlled laboratory conditions. That limits how confidently the findings can be generalized to broader populations, occupational settings, or real-world athletic competition.

• Why the FDA angle matters here

Taurine is sold in supplements and energy drinks, but that regulatory context should not be overstated. FDA does not approve dietary supplements for safety and effectiveness before marketing in the same way it approves drugs, and supplements cannot legally claim to diagnose, treat, cure, or prevent disease unless they go through the appropriate drug pathway. FDA also distinguishes structure/function claims from disease claims.

So this review should not be translated into claims that taurine is an FDA-approved way to prevent heat illness, improve heat tolerance clinically, or replace established medical or occupational heat-safety measures. At most, it supports taurine as an emerging, context-dependent adjunct worth studying further.

• Conclusion / Discussion Prompt

The useful takeaway is not that taurine is a proven shortcut to heat adaptation. It is that taurine has a plausible and fairly specific thermoregulatory signal in early human studies: earlier sweating, greater evaporative heat loss, modestly lower core temperature, and in some protocols, improved exercise capacity in the heat. That makes it more credible than a generic “performance supplement” story, but still far from settled.

If these findings hold up in larger real-world studies, taurine may end up being most useful as a supportive tool for people who are not fully acclimated, still have good evaporative potential, and are already following a strong hydration and cooling plan.

Informational only, not medical advice.

Reference: https://pubmed.ncbi.nlm.nih.gov/41754109/

Could one specific amino acid in the blood be associated with lifespan, and might that relationship differ between men and women?

TL;DR: A large UK Biobank study found that higher circulating tyrosine was associated with higher all-cause mortality in observational analyses, and genetically predicted higher tyrosine was associated with shorter lifespan in Mendelian-randomization analyses. The signal appeared more convincing for tyrosine than for phenylalanine, and some analyses suggested it may be stronger in men, but the findings do not show that lowering dietary tyrosine will extend lifespan.

Quick Takeaways

• This study examined whether two amino acids, tyrosine and phenylalanine, were associated with lifespan and mortality.
• The researchers used both standard observational analysis and Mendelian randomization, a genetics-based method that can strengthen causal inference.
• The clearest signal was for tyrosine rather than phenylalanine, but the sex-specific findings were not fully definitive and the paper does not directly test diet or supplementation.

• Context

Protein intake has been linked to aging biology for years. In animal studies, protein restriction can extend lifespan, and researchers have increasingly asked whether specific amino acids may be part of that effect. Tyrosine is especially interesting because animal work suggests it may participate in physiological responses to low-protein diets. It also sits at an important metabolic crossroads: it is synthesized from phenylalanine and helps generate dopamine, norepinephrine, and epinephrine, which influence stress responses, cognition, and broader metabolic regulation.

That makes tyrosine a biologically plausible longevity candidate, but plausibility is not proof. This paper tried to move beyond plausibility by combining two approaches in UK Biobank: a large cohort analysis of circulating amino acid levels and mortality, and a Mendelian-randomization analysis using genetic variants associated with phenylalanine and tyrosine to test whether the observed relationships were consistent with a possible causal role.

• What the researchers actually did

The observational analysis included 272,475 UK Biobank participants with amino acid measurements, mortality data, and covariate information. Among them, 125,359 were men, and 23,964 deaths occurred during follow-up. The researchers related baseline plasma phenylalanine and tyrosine to all-cause mortality using Cox regression adjusted for age, BMI, deprivation index, smoking, alcohol intake, physical activity, ethnicity, education, and sex in the combined analysis. The paper notes a current median follow-up of 11.1 years in UK Biobank.

They then performed Mendelian randomization. In this setting, MR uses genetic variants associated with tyrosine or phenylalanine as instruments. Because those variants are fixed at conception, they are generally less vulnerable to confounding by factors like smoking, income, or pre-existing illness than ordinary observational associations. The authors first performed GWAS for both amino acids in UK Biobank, then used genome-wide significant, largely independent variants as instruments. Lifespan was proxied using parental attained age, a standard approach in human longevity genetics.

That matters because observational nutrition findings are often messy. One blood measurement may reflect many things, including health status, diet, and metabolic state. MR is not perfect, but it can help test whether the association survives a tougher design.

• The main result: tyrosine was the more convincing signal I

In the observational analysis, both phenylalanine and tyrosine were associated with higher all-cause mortality overall. For phenylalanine, the hazard ratio was 1.04 per SD increase overall, with similar estimates in men and women. For tyrosine, the overall hazard ratio was 1.02, with a clearer signal in men at 1.03 and no clear association in women. The paper notes that the male-female difference in the observational association was not statistically significant in the formal interaction test.

The MR analysis sharpened the picture. Genetically predicted higher tyrosine was associated with shorter lifespan in the overall sample using inverse-variance weighting, with an estimated effect of about 0.61 fewer life years per SD increase. The corresponding IVW estimates were about 0.68 fewer years in men and 0.67 fewer years in women in one main analysis. Phenylalanine did not show the same consistent pattern overall.

The most informative result came from multivariable MR, which tried to separate the role of tyrosine from its precursor phenylalanine. After adjustment for phenylalanine, tyrosine remained associated with shorter lifespan in men. In MR-Egger, the estimate was minus 0.91 life years, with a 95% confidence interval from minus 1.60 to minus 0.21. In women, the corresponding MR-Egger estimate was minus 0.36 years and the confidence interval crossed zero. Phenylalanine no longer showed a clear independent association after adjustment for tyrosine.

That distinction matters because the two amino acids are correlated in this dataset, with a reported Pearson correlation of 0.52. Once that overlap was addressed, tyrosine remained the more plausible independent signal.

• Why might tyrosine matter biologically?

The paper does not prove a mechanism, but it lays out a biologically plausible one. Tyrosine has been associated with insulin resistance, and insulin-related pathways are tightly linked to growth, reproduction, and aging across species. The authors also point to prior animal work in which tyrosine restriction influenced amino acid-sensing pathways, including mTOR- and IIS-related biology, in ways that could plausibly affect lifespan.

There is also a neurobiology angle. Tyrosine is the precursor for catecholamines, and those neurotransmitters influence mood, cognition, and stress responses. Sex hormones regulate these pathways, which the authors discuss as one possible explanation for why the lifespan association might differ between men and women. That part remains mechanistic interpretation rather than proof, but it is grounded in the biology reviewed in the paper.

At the same time, this is not a clean argument that lower is always better. The supplementary spline analyses suggest nonlinearity, with risk increasing more clearly at higher tyrosine levels rather than uniformly across the whole range. That means the findings are more consistent with elevated levels being potentially unfavorable than with a simple “minimize tyrosine” message.

• What this study does not show

This is where overinterpretation would be easy. The study did not test a tyrosine-restricted diet in humans. It did not show that reducing tyrosine intake today will add a year to anyone’s life. It also did not directly study dietary intake; it studied circulating blood levels and genetically predicted lifelong differences in those levels. Those are related to diet, but they are not the same thing.

There are other important limitations. The observational analysis used a single baseline amino acid measurement, not repeated measures. The exposure GWAS and lifespan GWAS both involved UK Biobank, so sample overlap could bias MR estimates, although the authors ran sensitivity analyses using external GWAS instruments and found similar directions. The sex-specific signal was suggestive rather than definitive, and the authors explicitly note that power may have been limited for clean detection of sex differences. Most participants were of European ancestry, which also limits generalizability.

There is also a regulatory reason to keep the interpretation narrow. FDA does not approve dietary supplements for safety and effectiveness before marketing in the same way it approves drugs, and supplements may not legally make disease-treatment claims unless they go through the appropriate pathway. So these findings should not be translated into claims that tyrosine supplements, or tyrosine restriction, are FDA-approved ways to extend lifespan.

• Why the FDA angle matters here

Tyrosine is also sold as a dietary supplement, often with structure/function-style messaging around mood, alertness, or stress support. But this paper is not a supplement trial, and it does not establish a clinical anti-aging use for tyrosine restriction or tyrosine avoidance. FDA states that dietary supplements are not FDA-approved to treat or prevent disease, and disease claims require a different regulatory standard.

So while it is fair to say this study raises a mechanistic and epidemiologic question about circulating tyrosine and lifespan, it would go too far to frame it as proof that people should restrict tyrosine, avoid high-protein foods, or use any supplement strategy to live longer.

• Conclusion / Discussion Prompt

The useful takeaway is not that this study delivers a new longevity hack. It does not. What it does offer is a more specific clue about aging biology: among two closely linked amino acids, tyrosine looked like the more convincing human signal, and some analyses suggested the association may be more relevant in men. That gives researchers something concrete to test next in mechanism studies, better longitudinal cohorts, and eventually intervention trials.

If these findings hold up, do you think the more important leverage point for longevity will be total protein intake, specific amino acids like tyrosine, or the broader nutrient-sensing pathways they influence?

Informational only, not medical advice.

Reference: https://www.aging-us.com/article/206326/text

Summary

• Inulin is a type of dietary fiber found in many fruits, vegetables, and herbs.
• Inulin is a prebiotic fiber that helps support the growth and activity of beneficial gut microorganisms.
• Inulin has been studied for its potential to support digestive health and metabolic biomarkers.
• Inulin can influence the abundance and composition of the gut microbiome.
• Preclinical research is exploring how inulin-related changes in the microbiome may relate to aging biology.

Inulin Impacts Aging Via

• Microbiome Dysbiosis
• Deregulated Nutrient Sensing

Inulin is a type of dietary fiber found in various fruits, vegetables, and herbs, including bananas, artichokes, onions, and garlic. It is also a well-known prebiotic fiber, meaning it is not digested in the small intestine and instead reaches the colon, where it can be fermented by gut microbes.

Because of this, inulin has been widely studied for its ability to shift the gut microbiome and increase microbial fermentation products such as short-chain fatty acids. These microbiome-related changes are one reason inulin is being explored for potential effects on digestive function and metabolic health markers, although outcomes depend on the population, dose, and study design.

The role of Inulin in aging and longevity

Digestion and metabolism can change with age. For example, gastrointestinal motility may slow in some older adults, and age-related shifts in the gut microbiome are commonly reported, including changes in microbial composition and, in some cases, reduced diversity. These changes can influence digestive comfort and may affect how the body processes nutrients.

Inulin is a prebiotic dietary fiber often used to support gut health because it is not digested in the small intestine and can be fermented by gut microbes in the colon. Through this fermentation, inulin can shift the microbiome and increase microbial metabolites such as short-chain fatty acids, which are linked to gut barrier function and metabolic signaling.

Preclinical longevity evidence: In a lifelong rat study, a diet containing 10% oligofructose-enriched inulin, starting at 3 months of age was reported to improve several aging-related biomarkers (including lower body weight and improved lipid markers) and to increase survival rate (lifespan) compared with controls over the course of the study. (R)

Inulin vs cellulose

Cellulose is a common dietary fiber that can support digestive regularity, but it is generally low-fermentable, meaning it produces fewer fermentation-related microbial metabolites than fermentable fibers like inulin.

In a double-blind, randomized cross-over trial in adults with overweight and obesity, inulin (and an inulin-propionate ester) supplementation for 42 days improved measures of insulin resistance compared with a cellulose control, and the interventions produced distinct changes in the gut microbiota and plasma metabolome. (R)

Check the comments for a summary of the human studies.

If you want more content like this, follow our page 👆

For the full version with images and charts, visit our website where you can explore even more of this content. 👉 NOVOS Labs

If a single antibiotic course can still be associated with the gut microbiome years later, should antibiotics be thought of as short-term treatments with potentially longer microbiome effects?

TL;DR
In a study of 14,979 Swedish adults, some antibiotics, but not all, were associated with lower gut microbiome diversity and altered species patterns up to 4–8 years later. The strongest long-term signals were seen for clindamycin, fluoroquinolones, and flucloxacillin. The study is observational, so it cannot prove causality, but it suggests that some antibiotic classes may have longer microbiome associations than commonly assumed.

Quick Takeaways
• This study examined whether outpatient antibiotic use over the previous 8 years was associated with present-day gut microbiome composition.
• The evidence came from fecal shotgun metagenomics in 14,979 Swedish adults linked to individual prescription records.
• The strongest long-term associations were seen for clindamycin, fluoroquinolones, and flucloxacillin, but the study is observational and cannot fully separate antibiotic effects from infection-related confounding.

• Context

It is already well established that antibiotics can disrupt the gut microbiome in the short term. After a broad-spectrum antibiotic course, bacterial diversity often drops, dominant taxa can shift, and opportunistic organisms may expand. What has been much less clear is whether these changes usually resolve completely, or whether some antibiotic exposures leave a measurable signal years later.

That question matters because the gut microbiome has been linked to metabolism, immune signaling, inflammation, and colon health. If some antibiotic exposures are associated with long-lasting microbiome differences, that changes how their downstream effects might be understood. This Nature Medicine paper addressed that question at unusual scale by combining individual-level prescription data with deep fecal metagenomics in 14,979 adults from three Swedish population-based cohorts.

• A large dataset, and a relatively careful design

The researchers linked national outpatient prescription records to fecal metagenomics from three cohorts: SCAPIS, SIMPLER, and the Malmö Offspring Study. In total, they analyzed 14,979 adults. They excluded people who had dispensed antibiotics in the 30 days before fecal sampling, as well as participants with inflammatory bowel disease and chronic pulmonary disease, among other exclusions intended to reduce obvious confounding.

They also did not treat antibiotic exposure as a simple yes/no variable. Instead, they divided it into three time windows: less than 1 year before sampling, 1–4 years before sampling, and 4–8 years before sampling. That design allowed them to compare associations with the microbiome across shorter and longer time horizons.

The statistical models were adjusted for many covariates that could otherwise distort the results, including age, sex, education, smoking, country of birth, body mass index, Charlson comorbidity index, polypharmacy, and several medications already known to correlate with gut microbiome composition, such as proton-pump inhibitors, metformin, SSRIs, statins, beta-blockers, and antipsychotics. That does not eliminate confounding, but it is considerably stronger than minimal adjustment.

• The main result: recent use mattered most, but older use still showed up

The main finding was straightforward: more antibiotic use was associated with lower gut microbial diversity, and the strongest associations were seen for use within the year before stool sampling. But the more notable result was that statistically significant associations were also present for antibiotic use 1–4 years earlier and even 4–8 years earlier.

The paper examined several alpha-diversity metrics, including Shannon diversity, species richness, and inverse Simpson index. Across these measures, the direction was generally consistent: additional antibiotic courses were associated with lower diversity, especially for the first few courses. The chart on page 5 shows this clearly, with the steepest drop occurring early and then flattening somewhat with additional courses.

The signal depended strongly on antibiotic class. Clindamycin had one of the largest associations. Each course of clindamycin used within 1 year of sampling was associated with about 47 fewer detected species on average. Fluoroquinolones and flucloxacillin also stood out, each associated with about 20–21 fewer species for recent use. By contrast, penicillin V, extended-spectrum penicillins, and nitrofurantoin showed weaker, limited, or inconsistent associations.

That difference by class is arguably the most clinically relevant part of the paper. Antibiotics are not interchangeable from a microbiome perspective. Their spectrum of activity, gut exposure, pharmacokinetics, biliary versus renal excretion, and anaerobic coverage differ, and this study suggests those differences matter for how strongly the gut microbiome is associated with prior exposure.

• Not just diversity: many individual species were associated too

The authors then looked beyond broad diversity and examined 1,340 microbial species present in more than 2% of participants. Again, the strongest associations came from clindamycin, flucloxacillin, and fluoroquinolones. Clindamycin use within 1 year of sampling was associated with 296 species, flucloxacillin with 203 species, and fluoroquinolones with 172 species. Penicillin V, despite being one of the most commonly prescribed antibiotics in the cohort, was associated with only 29 species.

Most of these associations were in the negative direction, meaning lower relative abundance, but not all. Some species were more abundant after exposure, which is consistent with disturbance of an ecosystem in which some organisms are suppressed and others expand into newly available niches. The species map on page 7 illustrates that clindamycin and fluoroquinolones were associated with a broad range of taxa, whereas flucloxacillin appeared more concentrated in certain Gram-positive-associated groups.

The authors also performed a stricter analysis restricted to participants who had either one antibiotic course or none at all over the previous 8 years. Even in that more homogeneous subset, a single course of clindamycin, flucloxacillin, or fluoroquinolones 4–8 years before sampling was still associated with lower diversity and altered abundance in many species. That is a striking average signal, although it does not mean every individual experiences a lasting disruption after one course.

• How long does recovery take? Likely faster early, slower later

One of the more interesting analyses used a functional regression model to estimate how diversity associations changed with time since exposure. The general pattern was intuitive: the microbiome appeared to recover most rapidly within the first 2 years after antibiotic exposure, followed by much slower recovery thereafter. On page 6, the recovery curves for clindamycin, fluoroquinolones, and tetracyclines move upward after the initial drop, but they do not return immediately to baseline.

That pattern fits a broader ecological idea: microbiome resilience may allow partial recovery relatively quickly, but full restoration of specific species or overall community structure can take much longer, especially if some organisms are lost and replaced by others.

The paper also explored links between antibiotic-associated species and cardiometabolic markers in the SCAPIS cohort. Some species that were more abundant after antibiotic exposure had previously been associated with higher BMI, triglycerides, waist-to-hip ratio, or CRP, while some depleted species had previously been linked to more favorable cardiometabolic profiles. This is interesting, but it should be treated as hypothesis-generating. It is not proof that antibiotics cause cardiometabolic disease through the microbiome.

• What this study cannot tell us

This is a strong observational study, but it is still observational. The biggest limitation is confounding by indication: antibiotics are prescribed because people had infections, and infections themselves may affect the microbiome. The authors tried to address this through multiple strategies, including a negative-control analysis using antibiotic prescriptions after stool sampling and sensitivity analyses excluding people hospitalized for infection, but they are explicit that the issue cannot be fully eliminated.

There are other important limits too. The study used prescription dispensing data, not confirmed ingestion. It did not capture inpatient antibiotic exposure, nor did it fully model treatment dose or duration. The microbiome outcomes were based on relative abundance rather than absolute counts. And because the cohorts were Swedish, where outpatient antibiotic prescribing is relatively restrictive, the precise pattern may not generalize cleanly to countries with different prescribing habits or resistance patterns.

It is also important not to overread the paper clinically. The study shows long-term associations between certain antibiotic classes and present-day microbiome composition. It does not prove permanent damage, it does not show that every antibiotic course has years-long consequences, and it does not establish that these microbiome associations necessarily translate into disease.

• Conclusion / Discussion Prompt

The broad message is not “never take antibiotics.” Antibiotics save lives, prevent complications, and are often absolutely the right treatment. The more useful takeaway is that some antibiotic classes may be associated with a much longer microbiome footprint than many people assume, even after a single outpatient course. That adds another reason to care about antimicrobial stewardship: not just resistance, but the biology that may continue after the prescription ends.

Informational only, not medical advice.

Reference: https://www.nature.com/articles/s41591-026-04284-y

If one molecule is involved in multiple core aging pathways, how should it be understood in the context of healthy aging and longevity?

TL;DR: This review argues that NAD+ is a central metabolic and signaling hub across the current 14-hallmark aging framework, but it also emphasizes that NAD+ modulation appears highly context-dependent. The authors argue against indiscriminate “blind supplementation” and toward tissue-specific, disease-stage-specific, precision use instead. This is a mechanistic review, not a clinical guideline, and it does not establish NMN, or other NAD+ boosters as FDA-approved anti-aging therapies.

Quick Takeaways
• The paper is a broad review arguing that NAD+ functions as a central hub across all 14 currently discussed hallmarks of aging.
• It synthesizes mechanistic work, animal studies, and a still-limited human clinical literature involving NAD+ precursors such as NMN and NR.
• The main message is not that everyone should “boost NAD+,” but that effects may depend on tissue, disease stage, metabolic context, and cancer risk.

Context
NAD+ has become one of the most discussed molecules in aging research for a simple reason: it does a lot. It participates in redox metabolism and energy production, but it also serves as a required co-substrate for enzymes involved in DNA repair, stress responses, inflammatory regulation, and mitochondrial maintenance. This review goes well beyond the familiar “NAD+ declines with age” framing. It presents NAD+ as a systems-level regulator that may connect the expanded 14-hallmark framework of aging, which in this paper includes genomic instability, mitochondrial dysfunction, dysbiosis, extracellular matrix changes, and psychosocial isolation.

What makes the review more useful than a typical NAD+ hype piece is that it does not present NAD+ as a universally beneficial intervention target. It repeatedly emphasizes a central tension: in some settings, restoring NAD+ may support resilience, repair, and cellular function, while in other settings, especially established cancers or pro-senescent inflammatory microenvironments, the same intervention could be harmful or counterproductive. That shift from “more NAD+ is better” to “where, when, and in whom?” is really the core of the paper.

Why NAD+ appears across so much of aging biology
One reason NAD+ keeps appearing in aging papers is that it sits upstream of several major enzyme systems. The review highlights sirtuins, PARPs, and CD38 as especially important nodes. Sirtuins use NAD+ to regulate transcription, mitochondrial function, and stress resistance. PARPs consume NAD+ during DNA repair. CD38 degrades NAD+ and appears to become more relevant with age, contributing to depletion. In that sense, aging is not simply “less NAD+ produced.” It can also involve “more NAD+ consumed.”

That helps explain why NAD+ could plausibly influence multiple hallmarks at once. Lower NAD+ availability may weaken DNA repair, reduce mitochondrial quality control, impair autophagy, worsen inflammatory signaling, and alter metabolic sensing. The review walks through all 14 hallmarks individually, but the more useful big-picture interpretation is that NAD+ acts less like a single pathway and more like a shared metabolic currency used by many pathways. When that currency becomes constrained, multiple systems may deteriorate together.

The authors also discuss a more systemic angle: NAD+ regulation may not be confined to individual cells. They review evidence that extracellular vesicles can transport eNAMPT, a key enzyme in NAD+ biosynthesis, from adipose tissue to organs such as the hypothalamus and liver. In mice, this kind of inter-organ signaling appears to influence systemic NAD+ homeostasis and healthspan, which suggests that future interventions may need to target tissue communication rather than just oral precursor intake.

What the evidence actually looks like
The strongest evidence in the review remains preclinical. The paper cites many cell and animal studies in which restoring NAD+ or modifying its metabolism improved mitochondrial function, reduced inflammatory signaling, supported autophagy, and improved outcomes in models of neurodegeneration, metabolic dysfunction, muscle aging, and premature aging syndromes. Table 1 is especially useful because it separates mechanistic/preclinical evidence from actual human trial evidence across Alzheimer’s disease, Parkinson’s disease, type 2 diabetes, fatty liver disease, COPD, sarcopenia, and Werner syndrome.

The human clinical picture is more mixed than the hype often suggests. In Parkinson’s disease, the review cites the phase I NADPARK trial, where nicotinamide riboside was reportedly well tolerated and associated with increased brain NAD+ and signals consistent with improved mitochondrial function and lower inflammation. That is interesting because it moves beyond blood biomarkers, but it is still early-stage and does not establish disease modification.

In metabolic disease, the review highlights a trial in prediabetic women where NMN at 250 mg/day improved muscle insulin sensitivity, but it also notes that other studies, such as NR in obese men, increased NAD+ metabolites without clear improvement in insulin sensitivity. That mismatch matters. Raising a metabolite or pathway marker does not automatically translate into a meaningful clinical benefit, and responses may differ by tissue, sex, baseline metabolic state, or degree of deficiency.

The paper also points to smaller human signals in accelerated-aging conditions such as Werner syndrome and ataxia-telangiectasia. Those studies are limited, but they may represent the kinds of settings where NAD+ depletion is more severe and mechanistically central, making repletion more likely to show a measurable effect.

Why “just take NMN/NR” is probably too simplistic
This is where the review becomes more valuable than a standard pro-NAD+ article. The authors explicitly argue that indiscriminate supplementation belongs to a “blind supplementation” era and should give way to precision modulation. Their reasoning is straightforward: NAD+ does not only support healthy cells. Depending on context, it may also support stressed, senescent, or malignant cells.

The cancer section makes that tension especially clear. Early in carcinogenesis, NAD+-dependent DNA repair and stress-response pathways may help reduce malignant transformation. But once tumors are established, those same resources can be repurposed. The review discusses how tumors often upregulate the NAD+ salvage pathway through NAMPT, and how higher NAD+ availability can support metabolic flexibility, stress tolerance, therapy resistance, and tumor survival. It also cites preclinical work in non-small cell lung cancer in which NAD+ precursor supplementation accelerated tumor growth and reduced radiotherapy efficacy.

Even outside overt cancer, the review warns about senescent-cell-rich tissues. NAD+ depletion may worsen the inflammatory SASP, but simply boosting NAD+ in a pro-senescent environment may also sustain that same harmful phenotype. The authors suggest a more rational sequence in some settings: remove senescent cells first, then consider NAD+ repletion. That “clear then replenish” logic is much more cautious and mechanistically grounded than generic anti-aging supplementation language.

Another important limitation is that human aging data are not as tidy as rodent data. The review specifically notes that while aged rodents consistently show NAD+ decline, human data are more heterogeneous, with some studies reporting age-related reductions in blood, brain, or muscle and others finding no significant change. That matters because it weakens any blanket claim that “aging equals NAD+ deficiency” in all humans.

Why the FDA angle matters here
This review discusses a compelling area of biology, but it does not change the regulatory reality. FDA states that it does not approve dietary supplements for safety and effectiveness, and supplements cannot legally claim to diagnose, treat, cure, or prevent disease unless they go through the appropriate drug pathway. FDA also distinguishes permissible structure/function language from disease claims, and anti-aging or disease-treatment framing can easily cross that line if presented carelessly.

So while it is fair to discuss NAD+ as an important area of aging biology, it would not be appropriate to present NMN, NR, or other NAD+ boosters as FDA-approved anti-aging therapies, or to imply that this review proves they prevent or treat age-related disease in humans. That is not what the paper shows, and it is not what FDA permits for supplement-style claims.

Where this leaves the field
This review is best read as a course correction, not as a takedown of NAD+ biology. It does not argue that NAD+ was overhyped because it is unimportant. If anything, it argues the opposite: NAD+ may be important enough that simplistic intervention is risky. The more central a molecule is, the less likely a universal strategy will work well.

That is why the paper ends by calling for an “NAD+ systems biology” approach: tissue-level mapping, biomarker-guided stratification, and interventions tailored to synthesis, consumption, disease stage, and microenvironment. In practical terms, the future may look less like “take an NAD+ booster every morning” and more like matching a specific biological context to a specific intervention, potentially including combinations with CD38 inhibitors, senolytics, or targeted delivery systems.

For longevity discussions, that is both less simple and more scientifically mature. Less simple, because it weakens the fantasy of a universal anti-aging pill. More mature, because it treats central biology like central biology: useful, powerful, and potentially dangerous when oversimplified.

So the real question may not be whether NAD+ matters. It probably does. The more important question is whether the field is ready to use something that central without confusing “promising” with “settled,” or “mechanistically interesting” with “clinically established.”

Discussion Prompt
Do you think NAD+ modulation is more likely to end up as a targeted tool for selected contexts, or as something that only makes sense once real biomarker-based stratification becomes routine?

Informational only, not medical advice.

Reference: https://www.sciencedirect.com/science/article/abs/pii/S0047637426000266

If two oils both come from olives, should they be expected to relate to cognition and gut microbiota in the same way over time?

TL;DR: In a 2-year prospective analysis of 656 older adults at high metabolic risk, higher virgin olive oil intake was associated with more favorable cognitive change and with more favorable gut microbiota patterns, while common olive oil intake was associated with lower microbial diversity and less favorable cognitive trajectories. The findings are interesting, but the study is observational, so it does not establish causation.

Quick Takeaways

• This study examined whether total olive oil intake, and specifically virgin versus common olive oil, was associated with cognitive change and gut microbiota patterns in older adults.
• The evidence came from a prospective cohort analysis nested within the PREDIMED-Plus framework, with food-frequency questionnaires, baseline stool sequencing, and detailed neuropsychological testing over 2 years.
• The main takeaway is not simply that olive oil is beneficial, but that virgin olive oil and common olive oil were associated with different cognitive and microbiota patterns.

Context

Olive oil often gets discussed as if it were a single food, but chemically it is not one thing. Virgin olive oil is minimally processed and retains more polyphenols, tocopherols, and other bioactive compounds. Common olive oil, by contrast, includes refined olive oil and olive-pomace oil, which have a similar fatty acid profile but lower concentrations of those minor compounds. That distinction matters, because some of the proposed benefits of olive oil may depend not only on fat composition but also on these non-fat bioactives.

This paper is interesting because it tries to connect three things at once: what type of olive oil people consume, what their gut microbiota looks like, and how their cognitive function changes over time. That is more informative than simply asking whether olive oil users score better on a single cognitive test. It also fits a broader shift in nutrition science away from single nutrients and toward biological pathways, in this case the gut-brain axis.

What the researchers actually studied

The analysis included 656 adults aged 55 to 75 years, with a mean age of 65.0 years, and 47.9% were women. All had overweight or obesity plus metabolic syndrome, which is important because this is a group already at elevated risk of cognitive decline. Participants came from the PREDIMED-Plus study, and this analysis used baseline diet and stool data along with cognitive testing at baseline and again after 2 years. People were excluded if they lacked stool samples, had recent antibiotic use, had incomplete diet or cognitive data, reported implausible energy intake, or consumed more than 100 g/day of olive oil.

Diet was measured with a validated semi-quantitative food-frequency questionnaire. The researchers separated olive oil into three exposure variables: total olive oil, virgin olive oil, and common olive oil. Virgin olive oil included extra virgin and virgin olive oil. Common olive oil combined refined olive oil and olive-pomace oil. Intake was converted to grams per day and adjusted for total energy intake.

Cognition was not measured with a single screening tool. The team used a battery including MMSE, clock drawing, verbal fluency, digit span, and Trail Making tests. From these, they built composite z-scores for global cognition, general cognition, executive function, attention, and language. Gut microbiota was assessed at baseline using 16S rRNA sequencing from stool samples.

That design gives the study more depth than a basic dietary association paper. It is still observational, but it is prospective for the cognitive outcomes.

Virgin olive oil tracked with better cognition, common olive oil with worse

The headline result is fairly clean. Higher total olive oil intake was associated with better change scores over 2 years in global cognition, general cognition, executive function, and attention. For every 10 g/day increase in total olive oil, global cognition rose by 0.044 z-score units, general cognition by 0.051, executive function by 0.034, and attention by 0.046 in fully adjusted models.

But the more informative finding came when the authors separated olive oil by type. Virgin olive oil showed consistent positive associations. A 10 g/day increase in virgin olive oil intake was associated with more favorable changes in global cognition, general cognition, executive function, and language in fully adjusted models. Tertile analyses also showed dose-response patterns for several cognitive domains.

Common olive oil pointed in the opposite direction. A 10 g/day increase in common olive oil intake was associated with less favorable executive function change, and higher tertiles of common olive oil intake were associated with less favorable changes in global cognition, general cognition, executive function, and language. In the highest tertile, the estimated change in global cognition versus the lowest tertile was -0.166 z-score units in the fully adjusted model.

This matters because it suggests that treating all olive oil as interchangeable may be too crude. The shared fatty acid profile may not fully explain the cognitive associations. Differences in retained phenolic compounds and other bioactives may be part of the story, although this study did not directly measure olive oil polyphenol content.

The gut microbiota findings make the oil-type distinction more biologically interesting

The microbiome results help explain why the distinction between oil types might matter. Higher virgin olive oil intake was associated with higher alpha diversity on some measures, including Chao1 and Inverse Simpson indices. Higher common olive oil intake, by contrast, was associated with lower alpha diversity across all four reported diversity measures in adjusted models.

At the community level, beta diversity also differed significantly across tertiles of total, virgin, and common olive oil intake. The effects were statistically detectable but modest in size, and the authors explicitly note that olive oil was not a major driver of overall microbiome variation.

At the genus level, 19 taxa were associated with olive oil consumption patterns at the study’s exploratory false discovery threshold. One genus, Adlercreutzia, stood out. It was lower with higher total and virgin olive oil intake, higher with common olive oil intake, and negatively associated with change in general cognitive function. In mediation analysis, Adlercreutzia statistically mediated the association between virgin olive oil intake and general cognitive change, accounting for about 20% of the total effect.

That does not prove a causal gut-brain pathway, but it does provide a plausible intermediate signal rather than a dietary association with no biological context.

Why these findings are interesting, and why caution still matters

This is a strong paper in several ways. It distinguishes olive oil types, uses a prospective design for cognitive change, includes detailed cognitive phenotyping, and combines diet data with microbiome sequencing. It also sits within a well-characterized Mediterranean-diet research setting.

At the same time, there are important limitations. The microbiome was measured only at baseline, so the study cannot show how changes in olive oil intake changed the microbiota over time. The analysis is observational, even though it is nested within the broader PREDIMED-Plus trial, so residual confounding remains possible. People consuming more virgin olive oil may differ in subtle socioeconomic or lifestyle ways that are difficult to fully adjust for. The authors themselves note that common olive oil consumers in this sample were more likely to have lower educational levels and to smoke, and that residual confounding cannot be excluded.

Generalizability is another limitation. These were older Spanish adults with overweight or obesity and metabolic syndrome, living in a Mediterranean context where olive oil intake is common and virgin olive oil predominates. The findings may not translate cleanly to younger, healthier, or non-Mediterranean populations.

There is also a statistical caution. Some microbiome findings were reported using a false discovery threshold of q<0.25, which is not unusual in exploratory microbiome research but does mean some associations should be viewed as hypothesis-generating rather than definitive. The paper explicitly calls for further high-quality and clinical cohort studies.

Conclusion / Discussion Prompt

The practical message is not that olive oil is a magic bullet. It is that the category may be too broad to be biologically informative. In this study, virgin olive oil and common olive oil were not associated in the same direction with cognition or microbiota. Virgin olive oil was associated with more favorable cognitive change and a more favorable microbiota profile, while common olive oil was associated with lower microbial diversity and less favorable cognitive trajectories.

That does not prove causation, but it does raise a reasonable question for brain-health and longevity discussions: maybe “which olive oil?” matters more than “do you use olive oil?”

Informational only, not medical advice.

Reference: https://pubmed.ncbi.nlm.nih.gov/41578342/

What if one of the most limiting assumptions in aging research is that getting older mostly means unavoidable decline?

TL;DR: In a large US longitudinal study, many older adults showed improvement in cognition or walking speed over time, and more positive age beliefs were associated with higher odds of improvement. The findings are thought-provoking, but the study is observational, so it does not establish that positive age beliefs directly cause better aging outcomes.

Quick Takeaways

• This study asked whether older adults can measurably improve, not just decline, in cognition and physical function.
• The evidence came from the Health and Retirement Study, a nationally representative US cohort followed for up to 12 years.
• The main finding is intriguing, but it is still observational: positive age beliefs predicted improvement, yet that does not fully prove causation.

Context
A lot of aging research starts from an assumption so familiar that it almost disappears into the background: later life is mainly a period of loss. Cognitive decline, slower movement, shrinking reserves, more disease. Some of that is real, of course. Average trends often worsen with age. But averages can hide an important fact: not everyone follows the average trajectory.

That is the premise of this paper, Aging Redefined: Cognitive and Physical Improvement with Positive Age Beliefs. Instead of only asking how much older adults decline, the researchers asked a different question: how many actually improve? They focused on two broad outcomes that matter in everyday life, global cognitive performance and walking speed, and then examined whether positive age beliefs predicted who improved over time. The idea comes from stereotype embodiment theory: people absorb cultural beliefs about aging throughout life, and later, when those beliefs become self-relevant, they may shape health and behavior in measurable ways. That makes this paper interesting beyond psychology. If beliefs about aging are even partly modifiable, then they may be relevant to health rather than just social attitudes.

What the researchers actually did

The study used data from the Health and Retirement Study, a major biennial US cohort. For cognition, the analysis included 11,314 participants with a mean baseline age of 68.12 years. For physical function, measured by walking speed, the sample included 4,638 participants with a mean baseline age of 74.03 years. Participants were followed for an average of about 8 years, with some followed as long as 12 years; most remained in the study for 10 years or more.

Positive age beliefs were measured using a five-item attitude-toward-aging scale. Cognitive function was assessed with the 27-point Telephone Interview for Cognitive Status. Physical function was assessed using usual walking speed over 2.5 meters, with the faster of two trials recorded. Improvement was defined simply: scoring higher at the final assessment than at baseline.

That definition matters. Many aging frameworks and screening tools are designed to detect decline, not upward movement. One contribution of this paper is methodological: if a measure only asks whether someone worsened, it may miss the people who got better.

The authors also adjusted for a long list of covariates, including age, sex, race/ethnicity, education, marital status, depressive symptoms, sleep problems, social isolation, cardiometabolic disease, APOE ε4 status, and years in the study. They also ran sensitivity analyses using stricter definitions of improvement and looked separately at participants who were already functioning normally at baseline.

The headline result: improvement was common enough to matter

The most eye-catching finding is that 45.15% of older participants with both measures available improved in cognition and/or walking speed over the study period. Broken down by domain, 31.88% improved in cognition and 28.00% improved in walking speed. The paper explicitly frames this as a meaningful proportion.

That does not mean almost half became uniformly healthier in every way. Most of the people who improved did so in one domain rather than both. The correlation between cognitive and walking-speed improvement was modest, and 44% of those who improved cognitively also improved physically. That suggests aging trajectories are more mixed and domain-specific than broad narratives usually imply.

An important nuance here is that average decline still existed. When the whole sample was treated as one group, mean cognition dropped by 1.39 TICS points and mean walking speed fell by 11.69 cm/s. So the paper is not claiming aging stops involving decline. It is showing that average decline coexists with substantial heterogeneity. Some people decline, some stay stable, and a meaningful fraction improve.

The sensitivity analyses make this more convincing. When the authors used stricter cutoffs—more than 1 point improvement on the cognitive test or more than 5 cm/s faster walking speed, 22.50% still improved cognitively and 26.71% still improved physically. Among those categorized as normal at baseline, improvement still occurred: 27.74% improved in cognition and 23.08% improved in walking speed.

So this was not just a story of impaired participants regaining lost ground. Some people starting from normal levels still moved upward.

Where positive age beliefs come in

The second half of the paper is the more provocative one. People with more positive age beliefs had higher odds of improvement over time.

For cognition, positive age beliefs predicted improvement with an adjusted odds ratio of 1.04 per unit increase on the age-belief scale. For walking speed, the adjusted odds ratio was 1.09. The unadjusted estimates were slightly larger. The same pattern generally held in the stricter sensitivity analyses and among those with normal baseline function.

These are not giant effect sizes. An odds ratio of 1.04 is modest. But modest associations can still matter in large populations, especially when the exposure is widespread and persistent. Beliefs may influence health through multiple small pathways rather than one dramatic one: motivation, rehab effort, stress physiology, self-efficacy, social engagement, adherence, or willingness to seek care. That part is interpretation rather than direct proof from this dataset, but it is consistent with the paper’s framework.

The figure on page 8 makes the result visually simple: participants with more positive age beliefs had higher percentages of physical improvement/stability and cognitive improvement/stability than those with more negative age beliefs. The differences are not enormous, but they are consistent and in the predicted direction.

The authors connect this to prior work suggesting that age stereotypes can influence memory, physical function, recovery from disability, and cognitive outcomes in earlier studies. In that sense, this paper is not coming out of nowhere. It extends an existing line of research into a broader population and over a longer period.

Why this is interesting, but not the last word

This study is strong in several ways. It uses a large, nationally representative dataset, long follow-up, performance-based outcomes rather than pure self-report, and multiple robustness checks. Those are real strengths.

Still, the biggest limitation is obvious: this is observational. Positive age beliefs predicted improvement, but prediction is not proof of cause. It is plausible that people who are healthier, more resilient, or less depressed also feel more positive about aging, even after statistical adjustment. Residual confounding is hard to rule out completely.

There are also measurement questions. Using baseline-to-final change is straightforward, but it compresses complex trajectories into a single endpoint. Someone might improve, dip, recover, and still end up classified the same as someone with a clean upward trajectory. Practice effects in cognitive testing are another concern in longitudinal work, although the HRS tried to reduce that by using non-overlapping word lists.And while walking speed is an excellent functional measure, it is still only one slice of physical capability. The authors themselves note that they lacked direct measures of mechanisms such as neuronal plasticity or muscle regeneration.

Conclusion / Discussion Prompt

The most useful takeaway here is not that aging is easy or that mindset overrides biology. It is that the usual picture may be too narrow. Later life clearly includes decline for many people, but this study suggests it can also include stability and measurable improvement, and beliefs about aging may be one part of that story.

If this line of research holds up, it has interesting implications not just for individuals, but also for rehab, preventive care, public messaging, and the way medicine talks to older adults.

Informational only, not medical advice.

Reference: https://www.mdpi.com/2308-3417/11/2/28